No retraction, correction or concern found when last checked on Oct 18, 2026.

Neuroinflammation in Alzheimer’s Disease

Isaac G. Onyango, Gretsen V. Jauregui, Mária Čarná and 2 more

Biomedicines · 2021 · Review · CC BY

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disease associated with human aging. Ten percent of individuals over 65 years have AD and its prevalence continues to rise with increasing age. There are currently no effective disease modifying treatments for AD, resulting in increasingly large socioeconomic and personal costs. Increasing age is associated with an increase in low-grade chronic inflammation (inflammaging) that may contribute to the neurodegenerative process in AD. Although the exact mechanisms remain unclear, aberrant elevation of reactive oxygen and nitrogen species (RONS) levels from several endogenous and exogenous processes in the brain may not only affect cell signaling, but also trigger cellular senescence, inflammation, and pyroptosis. Moreover, a compromised immune privilege of the brain that allows the infiltration of peripheral immune cells and infectious agents may play a role. Additionally, meta-inflammation as well as gut microbiota dysbiosis may drive the neuroinflammatory process. Considering that inflammatory/immune pathways are dysregulated in parallel with cognitive dysfunction in AD, elucidating the relationship between the central nervous system and the immune system may facilitate the development of a safe and effective therapy for AD. We discuss some current ideas on processes in inflammaging that appear to drive the neurodegenerative process in AD and summarize details on a few immunomodulatory strategies being developed to selectively target the detrimental aspects of neuroinflammation without affecting defense mechanisms against pathogens and tissue damage.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

1Aging is characterized by dysregulated immune and metabolic homeostasis where there is chronic sterile low-grade inflammation or inflammaging that involves cellular senescence, immunosenescence, mitochondrial dysfunction, defective autophagy and mitophagy, dysregulation of the ubiquitin–proteasome system, activation of the DNA damage response, meta-inflammation or metaflammation from chronic overnutrition or obesity, and gut microbiota dysbiosis. These are reflected by changes in circulating immune markers including C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α) and its soluble receptors (tumor necrosis factor receptor I (TNFR-I) and tumor necrosis factor receptor II (TNFR-II)), vascular cell adhesion molecule I (VCAM-I), d-dimer, and sirtuin signaling. The drawback of chronic subclinical inflammation is that it is an essential risk factor for increasing the incidence of degenerative diseases such as AD. There are currently an estimated 728 million persons aged 65 years or over in the world. In the next 30 years, this number is expected to more than double to exceed 1.5 billion in 2050 (https://www.un.org/development/desa/pd/news/world-population-ageing-2020-highlights (accessed on 20 March 2021)). Thus, the aging population vulnerable to inflammaging will significantly increase over the next few decades.

2AD is a chronic devastating neurodegenerative disorder in which increasing age is the strongest non-modifiable disease risk factor. There are currently no effective therapies for AD. It is clinically characterized by the progressive deterioration of memory and other cognitive functions. It is the leading cause of dementia, affecting 50 million people worldwide. Its neuropathological hallmarks include extracellular β-amyloid (Aβ) plaques and intracellular hyper-phosphorylated tau (p-τ) in neurofibrillary tangles, accompanied with synaptic and neuronal loss. AD can be classified as (i) familial or early-onset AD (EOAD) or (ii) sporadic or late-onset AD (LOAD). Both share almost similar pathophysiology. Three causative genes, including presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP), are involved in the pathogenesis of EOAD in an autosomal-dominant trait. LOAD, however, comprises most AD cases (>95%) where the greatest risk factor is advanced age, while the common genetic risk factor is an allelic variation in apolipoprotein E (Apo E). Recent large scale studies of AD genetics, employing genome-wide association studies (GWAS), whole exome sequencing (WES), and whole genome sequencing (WGS), have defined additional genes whose variants contribute to increased risk. These include Clusterin (CLU), Sortilin-related receptor-1 (SORL1), ATP-binding cassette subfamily A member 7 (ABCA7), Bridging integrator 1 (BIN1), phosphatidylinositol binding clathrin assembly protein (PICALM), CD2 associated protein (CD2AP), Complement component (3b/4b) receptor 1 (CR1), CD33, triggering receptor expressed on myeloid cells 2 (TREM2), and phospholipase D3 (PLD3). Intriguingly, more than 50% of validated gene variants are implicated in innate immune and microglial functions, including the top two AD risk genes, APOE and TREM2. Epigenomic analysis shows that AD GWAS loci are preferentially enriched in enhancer sequences involved in innate immune processes as well as endocytosis, cholesterol/sterol metabolism, and synaptic function. TREM2 enhances the rate of phagocytosis in microglia and macrophages; modulates inflammatory signaling; and controls myeloid cell number, proliferation, and survival, and it has been revealed that triggering TREM2 receptor in microglial cells is closely associated with the pathogenesis of AD. TREM2 modulates microglial functions in response to Aβ plaques and tau tangles. In early AD, the absence of TREM2 leads to increased amyloid pathology that progressively becomes worse owing to the loss of phagocytic Aβ clearance. In AD, TREM2 variants arise in part because of their reduced capacity to phagocytose Aβ.

3While compelling evidence indicates that AD has a multifactorial etiology, neuroinflammation plays a central role in its etiopathogenesis, owing to its capacity to exacerbate Aβ and τ pathologies. In vivo positron emission tomography (PET) studies provide direct evidence of increased microglia activation (inflammation) in the brains of AD patients. The levels of pro-inflammatory cytokines in AD patient serum and post mortem brain are elevated, and Aβ can activate the brains’ innate immune cells. The sustained inflammatory response in AD brains extends beyond a reaction to neuronal loss and involves microglia, astrocytes, oligodendrocytes, mast cells, cytokines, and chemokines, as well as complement. These collectively play an integral role in the onset and progression of the disease. Other early-onset processes involved in the etiology of the disease include mitochondrial dysfunction resulting in altered glucose metabolism and oxidative stress; chronic hypoperfusion; and neuronal cell cycle re-entry that leads to neuronal tetraploidization (NT), trisomy 21 mosaicism, and synapse loss. These processes may synergistically interact to facilitate the neurodegenerative process in AD.

4Here, we focus on recent progress made in understanding the role of inflammation in the etiopathogenesis of AD and describe a few immunomodulatory strategies being developed to selectively target the detrimental aspects of neuroinflammation without interfering with the defense mechanisms against pathogens and tissue damage.

2.1. Microglia

5Microglia are the CNS’s immune cells and are different from peripheral and other tissue-resident macrophages. They arise from yolk-sac fetal macrophages and are unique in their capacity for self-renewal. Other tissue macrophages develop from precursors that emerge later in life. They constantly survey their milieu and assess ongoing synaptic activity, mediate synaptic pruning, clear debris, and provide trophic support for neurons. In pathological situations such as chronic stress, the blood brain barrier (BBB) may become compromised, allowing peripheral hematopoietic cells to cross into neural tissue and become part of the parenchymal microglia/macrophage pool. In response to CNS insults such as neuronal injury or infection, microglia become activated to produce pro-inflammatory factors (M1 phenotype) or anti-inflammatory factors (M2 phenotype). An exquisite balance of anti-inflammatory mediators to heal and repair tissues and pro-inflammatory mediators to clear cellular debris and aggregated misfolded proteins is essential for the maintenance of a healthy CNS. With advancing age, microglia acquire an activated phenotype and release pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6. In AD, microglia react to pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs) to assume a M1 phenotype, leading to an exacerbation of inflammation and an acceleration of disease progression (Figure 1). Preliminary findings implicate a link between Aβ and neuroinflammation. In AD brain slices, activated microglia surround both extracellular Aβ plaques and neurons containing neurofibrillary tangles (NFTs). It is thought that Aβ activate microglia, which then secrete IL1β, IL6, and TNFα, as well as (C-C motif) ligand (CCL 2/4/11), which lead to the recruitment of more microglia and astrocytes to the Aβ locus. Microglia phagocytize Aβ through a range of cell surface receptors, including cluster of differentiation (CD)-14, toll-like receptor (TLR)-2, TLR4, α6β1 integrin, CD47, and scavenger receptors such as CD36. In AD, the accumulation of Aβ throughout the brain results partly from the failure of microglia to remove extracellular Aβ and AD cortical specimens reveal that the microglia surrounding plaques have impaired Aβ uptake. It has been shown in human and animal studies that inflammation influences APP processing overall. Initially, microglial activation may serve to eliminate Aβ, but their chronic activation may amplify the amyloid cascade and lead to neurotoxicity. In rat intraventricular hemorrhage (IVH) model of AD, Aβ accumulation tracks with neuroinflammation and may contribute to the cognitive impairment.There is no consensus, however, regarding the relationship between in vivo microglial activation and Aβ plaque burden. Aβ has recently been suggested to be an antimicrobial peptide that fibrilizes in order to activate the innate immune defense system and protect the host from a wide range of infectious agents.

2.2. Astrocytes

6Astrocytes are the most abundant cell type in the CNS and a critical part of the tripartite synapse. They are highly sensitive to their environment and rapidly respond to CNS needs and insults. They also regulate the maturation of neurons and help maintain their function. They are found in various states of activation and can be neuroprotective (reducing inflammation and stimulating repair) or neurotoxic (promoting inflammation that may result in neurodegeneration). They respond to inflammatory molecules such as cytokines and chemokines and are able to detect aggregated proteins such as Aβ. They hypertrophy upon activation and upregulate glial fibrillary acidic protein (GFAP) expression. Reactive astrocytes are a distinct trait of AD patient brains and are also a feature of AD mouse model brains. Intralaminar astrocytes are atrophied and severely disrupted in post-mortem AD brains. In the 3xTg, which contain three mutations associated with a familial AD (APP Swedish, MAPT P301L, and PSEN1 M146V) mouse model, atrophic astrocytes appear in the entorhinal cortex (EC) as early as 30 days and are present until Aβ plaques begin to emerge at 12 months of age. This phenomenon also occurs in other AD mouse models including the 5xTG-AD, PDAPP-J20, and Swiss 3 mice. When astrocytes are created from familial and sporadic AD-induced pluripotent stem cells (iPSC), they have an atrophic phenotype in vitro. Inhibiting astrogliosis in AD mouse brains results in Aβ accumulation with increased histopathology and they are associated with cognition. This may result in a breach of the blood brain barrier (BBB), leading to an infiltration of peripheral immune cells, aggravating neuroinflammation and inducing neurotoxicity by impairing glutamate homeostasis, and generating altered Ca2+ signaling.

2.3. Oligodendrocytes

7The main function of oligodendrocytes is to provide support and insulation to the axons by forming myelin sheaths around nerve fibers. Their involvement in AD is not fully understood, although emerging evidence implicates their potential role in pathogenesis and progression of AD. Tsai et al. recently reported that oligodendrocytes are severely impaired in AD and, indeed, there is focal loss of oligodendrocytes and a reduction in myelin proteins near Aβ plaques. Aβ not only impairs the survival and maturation of oligodendrocyte progenitor cells (OPCs), but also hampers the formation of the myelin sheath. Neuroinflammation and oxidative stress may also contribute to oligodendrocyte dysfunction and death.

2.4. Myeloid Cells Other Than Microglia

8The other monocytic cells found in the CNS include perivascular macrophages that line blood vessels of the brain, macrophages within the choroid plexus, and meningeal macrophages in the leptomeninges. Dendritic cells, monocytes, and granulocytes are found in the meninges and are recruited to the brain during or after an insult or other pathology. The CNS-resident macrophages express scavenger receptors (SR) and TLRs that facilitate phagocytosis and degradation of Aβ. In SR knock out mouse models of AD, Aβ accumulates in the parenchyma and the animals have cognitive deficits. In the CD11c-DNR mouse model of AD, which expresses a dominant-negative form of the TGF-β receptor under the control of the CD11c promoter, the brain levels of Aβ are reduced by up to 90%, the Aβ plaques and cerebral vasculature are surrounded by macrophages, and the behavior of the animals is significantly improved. The migration of peripheral monocytes is dependent on C-C chemokine receptor type 2 (CCR2). Blocking transforming growth factor (TGF)-β signaling increases peripheral myeloid cell infiltration into the CNS and significantly reduces Aβ burden. It is still not exactly clear how myeloid infiltration into the brain contributes to damage or clearance of pathological proteins.

3. Defective Autophagy and Neuroinflammation

9Cells degrade protein aggregates and damaged organelles by autophagy and defective mitochondria by mitophagy. With advancing age, autophagy gradually subsides and this decline is linked to defective mitochondria and results in inflammaging. Damaged cellular and organelle components that accumulate as a result of inadequate autophagy are released as damage-associated molecular patterns (DAMPs). Dysfunctional mitochondria that are not eliminated by mitophagy release large amounts of mitochondrial DNA (mtDNA) into the cytosol and, together with ROS, metabolites such as ATP, fatty acids, Aβ, succinate, per-oxidized lipids, advanced glycation end-products, altered N-glycans, and HMGB1 are also recognized as DAMPs and trigger an innate immune inflammatory response by directly activating TLR9. This initiates the transcription of pro-inflammatory cytokines such as IL-6, TNF-α, IL-1β, and MMP-8 and activates the Nod-like receptor 3 (NLRP3) inflammasome, a key regulator of inflammation, to activate caspase-1 and facilitate IL-1β and IL-18 maturation as well as gasdermin D-mediated pyroptotic cell death. These inflammatory responses can be blocked by Pro-IL-1β degradation in autophagosomes. Further, the mitochondrial derived peptide (MDP) known as mitochondrial open reading frame of the 12S ribosomal RNA type-c (MOTS-c) reduces inflammation by inhibiting cytokines such as TNF-α and IL-6, while simultaneously promoting an anti-inflammatory response. MOTS-c stimulates IL-10 as well as signal transducer and activators of transcription 3 (STAT3) and aryl hydrocarbon receptor (Ahr), which inhibit NFκB expression and proinflammatory cytokine production. Another mitochondrial peptide, humanin, also has anti-inflammatory effects. The chronic sterile low-grade inflammation elicited may culminate in immunosenescence and compromise neuronal function. This may partly explain why dysregulated NLRP3 inflammasome activation is observed in AD). Eliminating damaged and dysfunctional mitochondria by mitophagy may prevent the hyperinflammation triggered by NLRP3 inflammasome activation.

4. Mitochondrial Dysfunction and Immunometabolism

10Mitochondrial dysfunction with decreased oxidative phosphorylation (OXPHOS) and increased glycolysis is observed in AD microglia. ]. Microglia exhibit high metabolic flexibility to cope with their high energy demands. Microglial activity becomes compromised with age as mitochondrial activity declines with age and especially in age-related diseases such as AD and they have a low mitochondrial turnover. Exposure to Aβ and tau activates a proinflammatory phenotype that is accompanied by a shift of the metabolic profile from OXPHOS to glycolysis. If the inflammatory process is prolonged, bioenergetic failure involving both glycolysis and OXPHOS occurs. In the 5XFAD mouse model of AD, enhancing glycolytic metabolism restores microglial phagocytic activity. Increased mitochondrial fragmentation is seen in cellular and animal models of AD and is associated with the increased pro-inflammatory cytokine production and neurotoxicity. These mitochondrial perturbations in activated microglia are propagated to other cell types, including astrocytes and neurons, exacerbating the disease outcome. Increased glycolysis and upregulated expression of glucose transporters as well as glycolytic enzymes in activated microglia are a well-established phenomenon. Increased microglial glycolysis is often coupled with the increased secretion of proinflammatory cytokines, exacerbating neurotoxicity, and escalating ongoing neurodegeneration. Glycolysis is upregulated in microglial cells during the early phase of AD, coupled with increased phagocytic activity followed by an “immune tolerant” phase, during which glycolysis and oxidative phosphorylation were both disrupted, with less phagocytic potential. Microglial activities can be restored through increasing metabolic functions with interferon-gamma (IFN-γ), resulting in increased microglial clustering around Aβ plaques, phagocytosis, and TNF-α production. Conversely, in AD models, oxidative phosphorylation increased phagocytosis and migration and reduced proinflammatory cytokine production.

5. Oxidative Stress and Neuroinflammation

11Neuroinflammation and oxidative stress are key pathologic signatures of AD. RONS are produced by all aerobic cells, and while they are essential signaling molecules, a redox imbalance is detrimental and plays an important role in the inflammatory process in aging as well as in AD. While cells of innate immunity produce copious amounts ROS within the central nervous system (CNS), it is not clear whether neuroinflammation induces oxidative stress or if it is the elevated levels of ROS that cause neuroinflammation, especially in a situation where there is already excess oxidant production in the face of age-associated weakened antioxidant defense.

12Elevated RONS levels damage primary cellular components including lipids, proteins, and DNA. Increased oxidative stress biomarkers (i.e., malondialdehyde (MDA), glutathione peroxidase (GSH-Px), and protein carbonyl (PC)) correlate with raised levels of inflammatory cytokines and both are associated with low cognitive performance in institutionalized elderly people. Mitochondria are the most important source of intracellular ROS and mitochondrial dysfunction leads to significant ROS increase. Alternative mechanisms that produce ROS include NADPH oxidase (NOX), immune activation, xanthine oxidase (XO), arachidonic acids (AA) metabolism, and so on. mtDNA mutations that accumulate with age disrupt the mitochondrial respiratory chain and lead to excessive mitochondrial ROS (mtROS) production, which, in turn, accelerates the emergence of new mtDNA mutations, leading to cellular senescence, further aggravating the inflammaging process. A vicious oxi-inflamm-aging cycle is thus created in aging and exaggerated in AD.

6. Cellular Senescence and Neuroinflammation

13Stimuli such as mitochondrial dysfunction, persistent DNA damage, and exposure to DAMPs can initiate cellular senescence. Senescent cells accumulate with aging and secrete proinflammatory and matrix-degrading molecules as part of a senescence-associated secretory phenotype (SASP), which is linked to age-related tissue inflammation and disease. Senescent cells are deleterious to non-senescent neighboring cells. They develop a SASP and secrete cytokines, chemokines, ROS, and proteases that create a noxious microenvironment that promotes inflammaging. Senescent neurons have been described in old rodent and human brains, suggesting a proliferation-independent senescence-like mechanism in post-mitotic cells including neurons. This concept is described as “amitosenescence” and involves an attempt by post-mitotic cells (particularly neurons) to re-induced cell cycle. SASP may account for several observed disease phenotypes in AD. The SASP is a very heterogeneous phenotype and the secreted components vary on the basis of cell type and triggering factors, but generally consist of interleukins (IL-1α, IL-1β, and IL-6), chemokines (IL-8 and growth-regulated-α protein), growth factors (fibroblast growth factor 2 and hepatocyte growth factor), metalloproteinases (interstitial collagenase (also known as MMP1), stromelysin 1 (also known as MMP3), and collagenase 3 (also known as MMP13)), as well as other insoluble proteins and extracellular matrix components. Their effects are mainly paracrine, but may become systemic as some of the soluble mediators may get into the circulation. Prominent SASP regulators include p38MAPK, NFκB C/EBPβ, GATA4, and mechanistic target of rapamycin (mTOR). Senescent markers are up-regulated in the astrocytes of AD patients and Aβ elicits senescence in astrocytes in vitro via ROS accompanied by p38, IL-6, and IL-8 up-regulation. When rat astrocytes are cultured, they exhibit signs of senescence including intense SA-β-gal staining, elevated ROS production, and bioenergetic deficits. This compromises their ability to maintain neurons and adversely affects the aging brain. Depleting human astrocytes of glutathione in vitro activates SASP-associated pathways (NF-kB and p38MAPK) and IL-6 secretion. In vitro, both human and rodent astrocytes upon replicative or stress induced senescence become flattened and enlarged and adopt senescence-associated heterochromatin formation (SAHF) and have elevated levels of p53, p21CIP1, p16INK4a, and SA-β-gal. Further, oligodendrocyte precursor cells (OPCs) in an AD mouse model show a proinflammatory phenotype along with increases in p16 and p21 expression near Aβ plaques, and Aβ can induce senescence in cultured OPCs. Mouse models of Aβ plaque accumulation lend credence to the fact that OPCs localize to plaques. In the 3xTg-AD mice AD,158], hypertrophic OPCs infiltrate and accumulate around Aβ plaques and in the TgAPP/PS1 mouse model, the OPCs surrounding Aβ plaques have increased Cdkn2a mRNA expression, and SA β-gal and IL-6 levels (SASP factor) reflect what is seen in the human brain. This suggests that extracellular protein accumulation may negatively impact OPC function. While IL-6 and TGF-β mRNA are upregulated in AD patients, an inflammatory response from resident immune cells is also prominent in AD. Generally, senescent cells are cleared by natural killer cells (NKs) and macrophages. The CNS being under relative immune privilege, T-cells, NKs, and peripheral macrophages normally have limited access to the meninges and choroid plexus and far-limited access to the CNS parenchyma. However, this immune privilege is not absolute, and cells of the CNS are sensitive to inflammatory events occurring both within and outside of the brain. In the aging brain and especially in the AD brain, the BBB is compromised, leading to peripheral immune cell infiltration. This allows the infiltration of peripheral immune cells and possibly infectious pathogens. Although microglia are the CNS resident macrophages, there is no evidence that they selectively kill senescent cells. Getting rid of CNS senescent cells would require infiltrating CD4+ T-cells, as peripheral macrophages appear to depend on these cells to kill senescent cells outside the CNS. As the clearance of senescent cells in the CNS is limited in non-aged healthy individuals, senescent cells, SASP, and secondary senescence may continue in the brain for several years or even decades.

7. Meta-Inflammation (Metaflammation)

14Late life obesity/metabolic disease and diabetes (T2DM) contribute to low-grade non-resolving inflammation and neuroinflammation and increase the risk of developing AD. AD has been referred to as “type 3 diabetes”. Adipose tissue inflammation in obesity is sterile, chronic, and low grade and affects the metabolic control of nutrient flow in adipose tissue, liver, muscle, and pancreas by inducing insulin resistance, and it differs from the typical inflammatory response to pathogens. Indeed, peripheral insulin resistance leads to decreased insulin signaling in CNS that is associated with an alteration in brain metabolism and activation of inflammatory pathways. Hyperglycemia in T2DM increases AD risk by exacerbating microglia and astrocyte-mediated neuroinflammation and neuronal injury. Individuals with advanced age, obesity, T2DM, or hypercholesterolemia are more likely to be affected by AD.

8. Exercise and Inflammation

15Endurance exercise (EE) has anti-inflammatory properties that can reduce the risk of several metabolic disorders. Some of these effects arise from the IL-6 secreted from skeletal muscles into circulation in response to EE and include the acute phase of immune response as well as glucose and lipid metabolism, and have been shown to reduce the risk and severity of many chronic diseases, and the benefits extend to the brain. One of the long-term immunometabolic adaptations is mediated by energetic stress, which induces beneficial molecular adaptations in adipose tissue and immune cells. In the brain, this results in the upregulation of IL-10 that activates mouse microglia and astrocytes. The modulatory effects of exercise on inflammation both centrally and peripherally have a protective effect on cognitive function and may be beneficial to patients with AD, as it elevates levels of circulating growth factors (such as insulin-like growth factor 1, IGF-1) and neurotrophins (such as the brain-derived neurotrophic factor, BDNF).

9. Gut Microbiota and Inflammation

16The gut microbiota is less diverse with age and contains more Bacteroides, compared with the higher presence of Firmicutes in younger adults. There is also a correlation between microbial diversity, frailty scores, and environmental factors such as dietary pattern in elderly individuals. These changes can initiate dysbiosis, and the prevalence of pathogenic species in the intestinal microbial composition results in elevated levels of systemic proinflammatory markers (IL-6, IL-8, TNF-α, and CRP) associated with the pathogenesis of AD. The microbiota can also modulate events in the brain via vagus nerve activation, neuropeptide and neurotransmitter release, short-chain fatty acids (SCFA), α-amino-β-methylaminopropionic acid (BMAA), and lipocalin-2 release. These signals reach the brain and influence the microglial maturation and activation, facilitating immune surveillance, regulation of hypothalamic-pituitary-adrenal (HPA) axis, synaptic pruning, and clearance of debris. Further, neurobehavioral complications associated with peripheral infections may be facilitated by advancing age because hippocampal processing is more easily disrupted when the peripheral innate immune system is stimulated in older animals.

10. Complement in the Brain

17While complement proteins are mainly synthesized in the liver, complement proteins and their cognate receptors and regulators are expressed throughout the CNS. The intact blood–brain barrier (BBB) restricts and prevents access of complement proteins from the periphery. Local production is, therefore, particularly important for innate immune defense in the healthy brain. Even in the healthy brain, however, there are regions where the BBB is compromised, particularly in the aged normal brain where evidence of barrier loss in and around the hippocampus has been described, and this is more severe in the AD brain. In the post-mortem AD brain, complement protein and activation products surround plaques and tangles. Numerous mediators are implicated, including ROS and activation of tissue metalloproteinases, but the dominant pathway to BBB breakdown is inflammation, either central or systemic. BBB impairment in AD may be much more subtle, localized to areas of pathology, and affecting specific transport processes—e.g., the transport of Aβ. C3a/C3aR signaling via intracellular Ca2+ mediates vascular endothelial cadherin junction and barrier integrity in an in vitro model of the BBB. Microglial reactivity can be inhibited by inactivation of C3aR1, and this restores hippocampal and cortical volumes in aged brains, suggesting an association between impaired BBB, inflammation, and neurodegeneration. Complement plays complex roles in brain homeostasis and likely has both protective and exacerbating effects on disease. Evidence suggests that complement restricts Aβ plaque formation and aids clearance of plaque components, but also contributes to the switch of microglia and astrocytes into activated neurotoxic cells that drive the pathology.

11. Possible Intervention for Neuroinflammation in AD

18In chronic inflammation, the initial response is not adequately resolved, leading to the accumulation of TNF, IFNs, and IL-6 as well as immune cells, apoptotic cells, and debris at the site of insult/injury, compromising functional homeostasis. While there are concerted efforts to develop compounds that target specific facets of inflammation, viable strategies should seek to resolve neuroinflammation without impacting the defense mechanisms against pathogens and tissue damage. We depict a few immunomodulatory strategies being developed to delay the onset and/or progression of AD.

11.1. Targeting TNF-α

19TNF-α plays a central role in the initiation and maintenance of the inflammatory response, and effects of TNF-α in the CNS can be either homeostatic or pathophysiological. It regulates synaptic plasticity, microglial activation, astrocyte-induced synaptic strengthening, and glutamatergic transmission in the healthy CNS, while in pathological conditions, the copious amounts of TNF-α released by microglia mediate a chronic inflammation that leads to neuronal dysfunction and cognitive impairment, as seen in transgenic mouse models of AD. 5XFAD/Tg197 AD/TNF double-transgenic mice develop a human TNF-α (huTNF-α) expression induced Aβ plaques deposition and arthritis. Systemic treatment with infliximab, an anti-huTNF-α antibody that does not cross the BBB, protects neurons, reduces gliosis, and prevents infiltration of peripheral immune cells without altering brain huTNF-α levels. In AD patients, TNF-α not only co-localizes with Aβ plaques in the brain, but the levels are also elevated in the plasma and cerebrospinal fluid (CSF) and correlate with the severity of the disease. TNF-α specific monoclonal antibodies such as infliximab, adalimumab, and the recombinant fusion proteins etanercept have been developed for peripheral inflammatory conditions and have been demonstrated to be effective and well tolerated in patients with a wide range of inflammatory conditions. These drugs have been tested on AD rodent models via central and peripheral routes of administration. Adalimumab significantly attenuated neuronal damage and neuroinflammation, decreased beta secretase-1 protein expression and Aβ1-40 plaques, and improved cognitive functions in Aβ1-40-injected mice, suggesting possible clinically meaningful outcomes in patients with AD. Indeed, patients with rheumatic disorders that are treated with TNF-blocking agents have a lower risk for developing AD. XPro1595, a second-generation TNF-α inhibitor, targeting only the soluble form of TNF-α, thus preserving the neuroprotective transmembrane TNF-α signaling pathways, has been evaluated in three different mouse models of AD. Peripherally administered, XPro1595 reduces brain amyloid deposition and age-dependent increase in activated immune cells and improves synaptic function. Locally administered, XPro1595 reduced pre-plaque Aβ pathology in 3×TgAD mice with concomitant reduction in microglia activation and improvement of synaptic and cognitive functions in aging rats. While new TNF-α inhibitors that are able to cross BBB are being developed, the use of the above compounds is limited to peripheral targeting of TNF-α as they are not able to readily cross the BBB.

20An alternative approach under consideration for AD is the development of inhibitors of TNF-α synthesis. Thalidomide and its derivatives, also referred to as immunomodulatory imide drugs (IMiDs), target the 3′-untranslated region (3′-UTR) of TNF-α mRNA, inhibiting TNF-α cytokine production. Compared with similar anti-inflammatory drugs, currently marketed IMiDs have improved BBB permeability and bioavailability, making them viable candidates for neurological disorders. Chronic thalidomide administration significantly reduces both astrocytes and microglia activation, and Aβ generation in brains of APP23 transgenic mice through inhibition of β-secretase (BACE1). 3,6′-dithiothalidomide (3,6′-DT) effectively lowers TNF-α, nitrite, and secreted amyloid precursor protein (sAPP) levels in vitro in LPS-activated macrophage-like cells. It also significantly reduces central and systemic TNF-α production and neuroinflammatory markers and restores hippocampal neuronal plasticity in LPS-challenged rats. Chronic 3,6′-DT administration ameliorates Aβ-induced neuroinflammation and microglial activation, preventing neurodegeneration and improving memory in an AD mouse model of stereotaxic intracerebroventricular Aβ1-42 and reduces multiple hallmark features of AD, including glia activation, phosphorylated tau protein, APP, Aβ peptide, and Aβ-plaque number along cognitive dysfunction in 3×Tg-AD mice, and leads to synaptic preservation. When treated with 3,6′-DT from 4 months of age, these mice showed only Aβ deposition within neurons, but no plaque or τ pathology is evident. This is associated with an increase in TNF-α levels and improved working memory performance. These promising preclinical studies using IMiDs indicate their potential of progressing from the bench to clinical trials and, eventually, to the bedside of AD patients.

11.2. Senolytics

21Senescent cells secrete proinflammatory cytokines, chemokines, and tissue-damaging proteases that negatively impact their surrounding microenvironment and accelerate aging and age-related diseases. Senolytics are drugs that selectively eliminate senescent cells and apparently provide beneficial effects in rodent models of aging, although a causal link between senescent cell accumulation and AD is yet to be established. Dasatinib, a tyrosine kinase inhibitor with BBB penetrance, decreases microgliosis and is neuroprotective in preclinical models of AD. Quercetin is a naturally occurring flavonoid that ameliorates AD pathology and protects cognitive and emotional function in aged triple transgenic AD disease model mice. In combination, Dasatinib and Quercetin (D + Q) have favorable side effect profiles, which makes them attractive for in-human trials. Fisetin (F) is flavonoid senolytic occurring in many plants, fruits, and vegetables that is widely available as a nutritional supplement. In old mice, intermittent F administration enhanced cognitive function. Intermittent administration of senolytics into a τ+ mouse line (rTg(tauP301L)4510) with mild τ overexpression that exhibit neurocognitive symptoms only after 22 months (equivalent to 70 human years) decreases brain senescent cells, neuroinflammation, and gliosis; enhances neuron density; partially restores lost cortical brain tissue; and decreases ventricular enlargement. These changes are associated with the clearing of 35% of proinflammatory senescent NFT-containing neurons. Zhang et al. have demonstrated that D + Q clear brain senescent oligodendrocytes, decrease neuroinflammation, and improve memory acquisition and retention. Senolytics are selective for senescent, but not normal oligodendrocyte lineage cells derived from human brains as well as in the transgenic mice. In AD patient brains and brains of rTg4510 mice, only Olig2 and NG2 expressing OPCs that are associated with Aβ plaques exhibit a senescence like phenotype, while astrocytes, microglia, and oligodendrocytes that are exposed to Aβ do not. Treating these mice with senolytics selectively eliminates senescent cells, ameliorates inflammation and cognitive decline, and reduces Aβ accumulation.

11.3. Targeting the Inflammasome

22Targeting the NLRP3 inflammasome is gaining traction as a therapeutic strategy in inflammatory diseases. Several approaches endeavor to inhibit the activation of the NLRP3 inflammasome and reduce microglial cytokine production. The NLRP3 inflammasome significantly contributes to neuroinflammation and age-related cognitive decline and is potently activated by Aβ. Novel specific inhibitors of the NLRP3 inflammasome are currently in pre-clinical or clinical trials (ifmthera.com/pipeline). MCC950 (also known as CP-456,773 and CRID-3), a potent inhibitor of NLRP3, promotes microglial clearance of Aβ, reduces Aβ accumulation, and improves cognitive function in APP/PS1 mice. Both MCC950 and Inzomelid, another potent, selective, brain-penetrant NLRP3 inflammasome inhibitor, are expected to move into Phase II trials for a range of disorders, including Parkinson’s, Alzheimer’s and, motor neurone disease (https://www.europeanpharmaceuticalreview.com/news/111201/patents-for-nlrp3-inflammasome-inhibiting-compounds-granted-in-us-and-europe/. Accessed on 20 March 2021).

11.4. Targeting Immune Checkpoints

23The PD-1 (programmed cell death-1) receptor (an inhibitory immune checkpoint receptor (ICR)) is expressed on the surface of activated T cells. Together with its widely expressed ligand PD-L1, PD-1 plays an important role in maintaining immune homeostasis and self-tolerance. Persistent antigen stimulation and inflammation in pathological situations increase T cell surface expression levels of ICRs. This leads to their interaction with their ligands on antigen presenting cells (APCs) that “exhausts” the T cells, inducing a hypofunctional state. This mechanism could be manipulated to either quench or enhance the immune response as a therapeutic target and depends on recruited immunosuppressive regulatory T cells (Treg). This anti-PD-1/PD-L1 based immunotherapy has been effectively utilized for many cancers, and is now also a therapeutic strategy in AD animal models to induce a robust immune response against neurotoxic proteins. Indeed, immunoneutralization of tumor necrosis factor-related apoptosis inducing ligand (TRAIL), a modulator of Treg cell functions, reduces neuroinflammation in a mouse model of AD. In AD mouse models with advanced amyloid pathology, using PD-1 immune checkpoint blockers to overcome immune tolerance induces a robust systemic IFN-γ response with subsequent recruitment of monocyte-derived macrophages (MΦ) to the brain. This results in cerebral clearance of Aβ and improved cognition. Altering the brain immunological environment by inhibiting the PD-1/PD-L1 axis in a mouse model of tau pathology mitigates cognitive deficits and cerebral pathology. Supporting these findings, it has been shown that functional PD-1 is expressed in hippocampal neurons and anti-PD-1 treatment rescues synaptic transmission and plasticity and potentiates learning and memory. In the 5XFAD AD mouse model and DM-hTAU mouse model of frontotemporal dementia, neuroinflammation and cognitive deficits are shown. Although the immune checkpoint blockade based-therapy represents a promising therapeutic strategy for AD and age-related dementia, further research is needed before PD-1/PD-L1 based clinical trials are conceived for these disorders. In fact, it is important to note that several PD-1 antibody inhibitors developed for other indications activate the peripheral immune system, but fail to modulate monocyte-derived macrophage infiltration and progression of brain Aβ pathology in three different models of AD. A different study using the same PD-1 checkpoint blockade reported only a modest improvement of locomotor activity without any effect on cognition or tau pathology in a transgenic AD model. PD-1 inhibitors may be able to reduce plaque load and improve cognition.

11.5. Targeting CD38

24Daratumumab, a first-in-class humanized monoclonal antibody against the CD38 epitope, was approved and indicated for multiple myeloma patients refractory to conventional therapy. CD38 is a NAD glycohydrolase that is expressed by neurons, astrocytes, and microglial cells and plays an important role in neuroinflammatory and brain repair processes. Its role in AD was evaluated and it was found that deleting CD38 significantly reduces both soluble Aβ and plaque levels and improves spatial learning in mice. In an APPswePS1ΔE9 mouse model of AD, loss of CD38 results in significant reduction of Aβ plaques and an improvement of learning performance. In these APPswePS1ΔE9.CD38-/- mice, both β- and γ-secretase activities are reduced, suggesting that the loss of CD38 is neuroprotective in this AD model. So, while there is still no direct evidence implicating CD38 in NDDs, it might be a novel therapeutic target for modulating Aβ production and neuroinflammation in AD.

11.6. Targeting CD33

25CD33 has been identified by GWAS among the leading risk factors for AD. In the brain, it is exclusively expressed by microglia and infiltrating macrophages, and it has been shown in CD33–/– mouse models that knocking out CD33 reduces Aβ levels and amyloid plaque load in the brain. As APP processing is not altered in these animals, the phenotype likely results from a more efficient phagocytic clearance of Aβ. Other studies have shown that overexpression of ectopic CD33 in microglial line BV-2 cells reduces Aβ uptake. Indeed, subtype-selective sialic acid mimetic called P22 binds to CD33 and increases uptake of the toxic Aβ into microglial cells, making the sialic acid-binding site on CD33 an attractive pharmacophore for developing therapeutics that promote clearance of the Aβ.

11.7. Targeting IL-12/IL23

26Inhibition of the IL-12/IL-23 pathway by genetic ablation or pharmacological manipulation significantly reduces cerebral Aβ load and cognitive deficit. IL-12 and IL-23 subunit p40 production by microglia is increased in the APPPS1 AD mouse model. Genetic ablation of the IL-12/IL-23 signaling molecules p40, p35, or p19 reduces cerebral Aβ load and the biggest effect comes from ablation of p40 or its receptor complex.

27Moreover, immunizing of AD transgenic mouse models with Aβ42 prevents Aβ plaque formation along with decreased expression of the IL-12Rβ1 receptor in T cells. Co-blockade of IL-12 and IL-23 via targeting of p40 reduces Aβ burden. Indeed, antibodies against p40, IL-12, or IL-23 (European patent EP2661445A2) have been developed for the prevention or treatment of AD.

11.8. Targeting Th1 Response

28Glatiramer acetate (GA) (Copaxone), a synthetic analog of myelin basic protein, the first disease-modifying drug approved for treatment of multiple sclerosis (MS) can be used to safely boost T-cell responses without the risk of autoimmune disease, as it weakly cross-reacts with myelin-derived autoantigens. It is thought to mediate its effects by stimulating Th2 response, possibly by suppressing the inflammatory Th1 response, increasing the frequency and function of Treg cells, modulating CD8+ T cells, and exerting an immunomodulatory effect on B cells. In APPSWE/PS1dE9 double-transgenic, immunization with GA results in cerebral recruitment of pro-healing, highly phagocytic monocytes (Mo) and MΦ, greatly alleviating cerebral Aβ burden, reducing microgliosis and astrocytosis, resulting in improved hippocampal-based cognitive functions. Further, T cell-based vaccination with GA in the same animal model of AD leads to enhanced neurotrophic support and hippocampal neurogenesis. In APP-Tg mice, nasal vaccination with a proteosome-based adjuvant plus GA activates pro-healing microglia and robustly reduces Aβ fibrils levels. GA-stimulated MΦ protect neurons from Aβ-mediated synaptotoxicity both in vivo and in vitro and enhances cerebral recruitment of Mo-derived MΦ and reversing loss of cortical and hippocampal excitatory synapses in mouse models of AD. GA immunization enhances the expression of hippocampal early growth response protein 1 (Egr1), a protein negatively correlated with hippocampal Aβ plaque burden. GA-based vaccination could provide a new viable avenue for immune therapy for AD.

11.9. Targeting Microglial P2Y6 Receptor

29GC021109 is a small molecule that specifically targets microglial purinergic P2Y6 receptors, promoting their phagocytic activity and inhibiting the release of pro-inflammatory cytokines. It has been shown to be safe in a phase 1 trial of AD (www.alzforum.org/therapeutics/gc-021109;www.clinicaltrials.gov.ct2/show/study/NCT02386306) Accessed on 20 March 2021).

11.10. Cyclosporine and Tacrolimus

30Cyclosporine and Tacrolimus are inhibitors of calcineurin and are used as immunosuppressive agents to prevent post-transplant organ rejection and for the treat autoimmune diseases and tuberous sclerosis tumors. They have been shown to downregulate APP mRNA and protein expression protein in primary cultures of neonatal rat astrocytes. Tacrolimus significantly quenches Aβ- and LPS-stimulated secretion of pro-inflammatory cytokines and increases microglial uptake of fibrillar Aβ in vitro. It also reduces spleen cytokine levels, microgliosis, and Aβ plaque burden in APP/PS1 mice and ameliorates dendritic spine density deficits in plaque-bearing AD model mice. When APP/PS1 AD transgenic mice were treated with FK506, microgliosis, cytokine levels, and Aβ plaque load were significantly reduced. In Streptozotocin (STZ)-treated mice, Cyclosporine and Tacrolimus significantly reduce biochemical and histopathological alterations and age-related memory deficits, demonstrating their potential as therapeutic agents in cognitive dysfunctions, probably owing to their anti-amyloid, anti-oxidative, and anti-inflammatory properties.

11.11. Targeting p38MAPK

31Another novel therapeutic agent in the pipeline includes the orally active p38 MAPKα inhibitor Neflamapimod [VX-745] that is being developed as a disease modifying drug for AD, with phase 3 trials slated for late 2021. It is able to reduce IL-1β levels (NCT02423200) and improve patients’ attention and executive function.

11.12. CNS Targeting Anti-Complement Agents

32In vivo tests in Tg2576 that overexpress the human amyloid precursor protein (hAPP) 695 isoform that harbors the Swedish double mutation found in some cases of familial AD, and 3xTg, which contain three mutations associated with familial Alzheimer’s disease (APP Swedish, MAPT P301L, and PSEN1 M146V) mouse models of AD, have shown that the cyclic hexapeptide PMX205 that potently and noncompetitively inhibits complement C5a Receptor 1 (C5aR1) decreases Aβ and τ deposits, reduces activated glia, and improves cognition, while not affecting the levels and physiological functions of C1q and C3. ANX-M1/ANX005, a humanized immunoglobulin G4 recombinant antibody against C1q developed by Annexon Biosciences, is safe at high doses (200 mg/kg) and is neuroprotective, preventing synaptic loss when Aβ fibrils are injected into the lateral ventricles. It has proceeded to clinical trials. C3aR antagonist SB290157 could decrease amyloid load and microgliosis. It is important to recognize that complement may be neuroprotective early in the disease process by clearing debris, meaning that an intimate understanding of the therapeutic window where complement inhibition is most effect is crucial.

11.13. Novel Non-Steroidal Anti-Inflammatory Derivatives

33CSP-1103 (also known as CHF 5074 or Itanapraced) is a non-steroidal anti-inflammatory derivative lacking cyclooxygenase inhibitory activity. It is a microglia modulator that has the potential to inhibit Aβ plaque deposition, reduce tau pathology, restore normal microglial function by increasing phagocytosis, and decrease production of pro-inflammatory cytokines. It is currently in phase III clinical trials.

11.14. Calorie Restriction (CR)

34CR has been shown to improve lipid and glucose metabolism, quench inflammation, and improve cardiovascular health. This is thought to be via key nutrient and stress-responsive metabolic signaling pathways including IIS/FOXO, TOR, AMPK, Sirtuins, NRF2, and autophagy that additionally work towards lifespan extension by CR. Ultimately, the age-related proinflammatory upregulation of NFκB, IL-β, IL-6, TNF-α, and ROS is attenuated and the beneficial effects include enhanced cognitive response.

11.15. Metformin

35The biguanide drug metformin is a hypoglycemic drug widely prescribed to treat T2DM and metabolic syndrome. Its mode of action is to simulate CR, and it increases lifespan and limits the onset of age-associated diseases across species. It activates AMP-activated kinase (AMPK), enhances autophagy and mitochondrial function, and quenches inflammaging.

11.16. Endurance Exercise

36Endurance exercise (EE) is neuroprotective against AD. Exercise activates continuous oxidative stress that induces a series of counteractive mechanisms. These enhance mitochondrial function and mitigate ROS-induced neurotoxicity, i.e., mitohormesis, and this is especially important in the hippocampus, which is particularly sensitive to oxidative stress. EE also activates anti-inflammatory pathways.

11.17. Melatonin

37N-acetyl-5-methoxytryptamine (Melatonin), which is synthesized from tryptophan, is able to activate both proinflammatory pathways. It is also capable of suppressing proinflammatory processes including NO release, activation of cyclooxygenase-2, NLRP3, gasdermin D, TLR-4 and mTOR signaling, cytokine release by SASP, and Aβ toxicity under different conditions. In addition, it activates SIRT1 and upregulates Nrf2 while quenching NFκB activity and the release of IL-4 and IL-10, thus shifting microglia polarization towards an M2 phenotype.

11.18. Resveratrol

38Resveratrol has been shown to affect aging and lifespan in mammals. It is a potent natural SIRT1 activator that helps prevent aging-related decline in heart function and neuronal loss. Resveratrol can also attenuate the phosphorylation of the mammalian target of rapamycin (mTOR) and S6 ribosomal protein (S6RP) while ameliorating inflammation. Several cellular and animal studies show that SIRT1 is neuroprotective in neuroinflammation and neurodegenerative diseases. There are, however, conflicting results on the effects of resveratrol on AD subjects. In one study, AD subjects who received resveratrol for 52 weeks had a significant reduction in the expression of cerebrospinal fluid matrix metallopeptidase 9 (MMP-9) and inflammatory markers, but in another clinical trial of AD, resveratrol had no beneficial effects. A 26-week resveratrol treatment of healthy older adults improved memory performance and hippocampal functional connectivity. These findings suggest that SIRT1 may be the potential target treatment of neuroinflammation and neurodegenerative disorders.

11.19. Antioxidants

39Given the close association between oxidative stress and inflammaging, targeting detrimental ROS at the production stage without affecting ROS signaling may improve immune function and ameliorate neuroinflammation. Mitochondria-targeted antioxidants potently sequester reactive oxygen intermediates (ROIs) and confer greater protection against oxidative damage in the mitochondria than untargeted cellular antioxidants. These mitochondria-targeted antioxidants such as (10-(6′-plastoquinonyl) decyltriphenyl-phosphonium) (SkQ1), MitoQ, MitoTEMPOL, and MitoVitE prevent apoptosis by mitigating the oxidative damage more effectively than untargeted antioxidants such as 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox). Other such antioxidants include the following: 4,5-dihydroxybenzene-1,3-disulfonate (Tiron), which accumulate within the mitochondria by permeabilizing the mitochondrial membrane and astaxanthin, a mitochondrion-permeable antioxidant, that can penetrate the blood–brain barrier and is effective in preventing and treating macular degeneration.

11.20. Probiotics

40Gut microbiota are altered in the elderly; therefore, supplementation with specific strains of Lactobacilli and Bifidobacteria along with fructooligosaccharides and galactooligosaccharides may be beneficial. They have been shown to attenuate inflammaging by down regulating IFN-γ and TNF-α and upregulating IL-10. Alteration of the gut microbiota can induce changes in brain activity, which raise the possibility of therapeutic manipulation of the microbiome in AD and other neurological disorders. This field of research is currently undergoing great development, but therapeutic applications are still far away. The gut flora of cognitively impaired individuals and those with brain amyloidosis have an increased abundance of the pro-inflammatory species Escherichia/Shigella, while the abundance of anti-inflammatory species E. Rectale is reduced. Fecal samples from elderly AD patients with AD induce a lower expression level of p-glycoprotein (a key mediator of intestinal homeostasis) in intestinal epithelial cells in vitro. p-glycoprotein dysregulation leads to inflammatory disorders of the intestine. Altered gut microbiota with disrupted intestinal homeostasis and induced inflammation may lead to neurodegenerative diseases like AD via the gut–brain axis pathway. Thus, remodeling the gut microbiota may be a novel therapeutic strategy for AD. Altering gut microbiota through probiotics is a potential therapeutic strategy in AD.

11.21. Nutraceuticals

41The nutraceutical NT-020, which is a proprietary blend of blueberries, green tea, vitamin D3, and carnosine, has been shown to reduce inflammation in elderly rats and prevent age-related cognitive decline and enhance neurogenesis. Treating aged rats with NT-020 increases neurogenesis and serum from these animals’ rescued aged hippocampal neural stem/precursor cells (NPCs) and bone-marrow derived mesenchymal stem cells (MSCs) from age-related reduction in cell proliferation as measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 5-bromo-2′-deoxyuridine (BrdU) assays and serum from aged rats treated with NT-020 was not different from serum.

11.22. Essential Vitamins and Minerals

42Vitamins and minerals play major roles in boosting the immune system to protect against certain infections and inflammation. Vitamin E supplementation enhances IL-2 production and induces naive T cell proliferation. Vitamin C is a potent water-soluble antioxidant and plays an important role in maintaining redox homeostasis within cells and is protective against ROS released by phagocytes; therefore, it modulates the pro-inflammatory signaling pathways. It also augments humoral response and cell-mediated immunity. By accumulating within phagocytic cells, it enhances chemotaxis and phagocytosis and is essential for apoptosis and clearance from the site of infection of spent neutrophils by macrophages to decrease potential tissue damage. Vitamin C also reduces inflammation by blocking the synthesis of TNF, IL-6, and IL-1β, and has been shown in vitro to promote IgG and IgM production. Zinc (Zn) plays an important role as a structural and regulatory catalyst ion for several enzymes and transcription factors, and its deficiency results in significant decline in both the innate and adaptive immune responses and promotes systemic inflammation. Zn supplementation is associated with lower TNF-α levels and reduced oxidative stress as well as lower incidents of infection. Zinc deficiency activates the NFκB pathway and release of IL-2, IL-6, and TNF-α pro-inflammatory cytokines both in vivo and in vitro [A]. Zinc supplementation elicits inducible regulatory T cells production and decreases ROS production.

11.23. Flavonoids from Epimedium and Icariin

43Xia et al. have demonstrated that, in aged rats, Epimedium flavonoids and icariin attenuate the proinflammatory response while enhancing an anti-inflammatory response in inter alia the hippocampus, hypothalamus, and hypophysis, and mitigate neuroinflammation in aging. Icariin acts via the AMPK/mTOR/ULK1 pathway to increase neuronal autophagy and enhance brain function in aged Sprague–Dawley (SD) rats. Moreover, in the bilateral common carotid arteries occlusion (BCCAO) rat model of AD, which manifests as neuronal morphological damage along with Aβ deposition in the hippocampus and cognitive deficits of Aβ in rat hippocampus, oral administration of icariin reduces hippocampal expression of APP and BACE1, and induces the expressions of insulin-degrading enzyme (IDE) and a disintegrin and metalloproteinase domain 10 (ADAM10). This is accompanied by a decrease in TGF-β1 signaling via inhibition of Smad2/3 phosphorylation. Icariin also inhibits LPS induced IL-s and TNFa production while increasing expression of NFκB p-p65 and (TLR)4–myeloid differentiation factor 2 (TLR4/MD-2) complex. Tea flowers extract (TFE) has been shown to enhance p-AMPK and SIRT1 expression while reducing acetyl-NFκBp65 expression, and this is associated with a downregulation of IL-1β,TNF-α levels, inhibiting the pro-inflammatory response through the AMPK/SIRT1/NFκB pathway in aging rats.

12. Conclusions

44While multiple mechanisms likely contribute to the etiology and progression of neurodegeneration in AD, the pathogenic role of neuroinflammation is now well recognized and accepted. A sedentary lifestyle and unhealthy diet can accelerate the aging-associated chronic low-grade inflammatory process linked to neurodegeneration in AD. While a lack of pre-clinical models that can reliably mimic changes in both immune system and inflammatory machinery has complicated efforts to fully elucidate the underlying disease mechanism in a manner that would enable the manipulation of different pathways in order to delay the onset and/or progression of the disease, we describe a few that pivot on the inflammatory process (Figure 2). We discuss approaches including immunotherapeutic targeting immune checkpoint inhibitors, pharmaceuticals that selectively target the SASP microenvironment, and other detrimental aspects of neuroinflammation without affecting defense mechanisms against pathogens and tissue damage. Lifestyle changes that incorporate long-term EE regimen, CR/CR-mimetics and nutraceuticals, or a combination of these interventions may ameliorate inflammaging and its progression into AD. Remodeling the aging gut microbiota using probiotics or fecal transplants is likely to dampen the pro-inflammatory milleu and modulate the neurochemical and neuro-metabolic signaling pathways of the brain and protect against neuroinflammation. As there is a huge potential for therapies that modulate the neuroimmune response in AD, it is important to define the inflammatory stages to correlate to each phase of AD progression and clarify which processes are protective and which ones are detrimental, as well as identify suitable times, modes, and sites of intervention. This may facilitate a focused and functional therapeutic approach to alleviate age-related stress on the intracellular organelles, tissues, and systems and delay AD progression in aging.

References 517

1.
Pattabiraman G., Palasiewicz K., Galvin J.P., Ucker D.S. Aging-associated dysregulation of homeostatic immune response termination (and not initiation). Aging Cell. 2017;16:585-593.
Not in our library10.1111/acel.12589
2.
López-Otín C., Blasco M.A., Partridge L., Serrano M., Kroemer G. The Hallmarks of Aging. Cell. 2013;153:1194-1217.
Not in our library10.1016/j.cell.2013.05.039
3.
Spinelli R., Parrillo L., Longo M., Florese P., Desiderio A., Zatterale F., Miele C., Raciti G.A., Beguinot F. Molecular basis of ageing in chronic metabolic diseases. J. Endocrinol. Investig. 2020;43:1373-1389.
Not in our library10.1007/s40618-020-01255-z
4.
Franceschi C., Bonafè M., Valensin S., Olivieri F., De Luca M., Ottaviani E., De Benedictis G. Inflamm-aging: An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 2000;908:244-254.
Not in our library10.1111/j.1749-6632.2000.tb06651.x
5.
Li T., Huang Y., Cai W., Chen X., Men X., Lu T., Wu A., Lu Z. Age-related cerebral small vessel disease and inflammaging. Cell Death Dis. 2020;11:1-12.
Not in our library10.1038/s41419-020-03137-x
6.
Di Micco R., Krizhanovsky V., Baker D., d’Adda di Fagagna F. Cellular senescence in ageing: From mechanisms to therapeutic opportunities. Nat. Rev. Mol. Cell Biol. 2021;22:75-95.
Not in our library10.1038/s41580-020-00314-w
7.
Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? · 2018
No notice
8.
Franceschi C., Santoro A., Capri M. The complex relationship between Immunosenescence and Inflammaging: Special issue on the New Biomedical Perspectives. Semin. Immunopathol. 2020;42:517-520.
Not in our library10.1007/s00281-020-00823-y
9.
Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention · 2019
No notice
10.
Barbé-Tuana F., Funchal G., Schmitz C.R.R., Maurmann R.M., Bauer M.E. The interplay between immunosenescence and age-related diseases. Semin. Immunopathol. 2020;42:545-557.
Not in our library10.1007/s00281-020-00806-z
11.
Conte M., Martucci M., Chiariello A., Franceschi C., Salvioli S. Mitochondria, immunosenescence and inflammaging: A role for mitokines? Semin. Immunopathol. 2020;42:607-617.
Not in our library10.1007/s00281-020-00813-0
12.
Mitochondrial Dysfunction in Aging and Diseases of Aging · 2019
No notice
13.
Inflammaging: disturbed interplay between autophagy and inflammasomes · 2012
No notice
14.
Hallmarks of Aging: An Autophagic Perspective · 2019
No notice
15.
Fueling Inflamm-Aging through Mitochondrial Dysfunction: Mechanisms and Molecular Targets · 2017
No notice
16.
Defective Autophagy and Mitophagy in Aging and Alzheimer’s Disease · 2021
No notice
17.
Lopez-Castejon G. Control of the inflammasome by the ubiquitin system. FEBS J. 2020;287:11-26.
Not in our library10.1111/febs.15118
18.
Hegde A.N., Smith S.G., Duke L.M., Pourquoi A., Vaz S. Perturbations of Ubiquitin-Proteasome-Mediated Proteolysis in Aging and Alzheimer’s Disease. Front. Aging Neurosci. 2019;11:324.
Not in our library10.3389/fnagi.2019.00324
19.
Ioannidou A., Goulielmaki E., Garinis G.A. DNA Damage: From Chronic Inflammation to Age-Related Deterioration. Front. Genet. 2016;7:187.
Not in our library10.3389/fgene.2016.00187
20.
da Silva P.F.L., Schumacher B. DNA damage responses in ageing. Open Biol. 2019;9:190168.
Not in our library10.1098/rsob.190168
21.
Chen G., Yung R. Meta-inflammaging at the crossroad of geroscience. Aging Med. 2019;2:157-161.
Not in our library10.1002/agm2.12078
22.
Herradon G., Ramos-Alvarez M.P., Gramage E. Connecting Metainflammation and Neuroinflammation Through the PTN-MK-RPTPβ/ζ Axis: Relevance in Therapeutic Development. Front. Pharmacol. 2019;10:10.
Not in our library10.3389/fphar.2019.00377
23.
Vitale G., Salvioli S., Franceschi C. Oxidative stress and the ageing endocrine system. Nat. Rev. Endocrinol. 2013;9:228-240.
Not in our library10.1038/nrendo.2013.29
24.
Shintouo C.M., Mets T., Beckwee D., Bautmans I., Ghogomu S.M., Souopgui J., Leemans L., Meriki H.D., Njemini R. Is inflammageing influenced by the microbiota in the aged gut? A systematic review. Exp. Gerontol. 2020;141:111079.
Not in our library10.1016/j.exger.2020.111079
25.
Santoro A., Zhao J., Wu L., Carru C., Biagi E., Franceschi C. Microbiomes other than the gut: Inflammaging and age-related diseases. Semin. Immunopathol. 2020;42:589-605.
Not in our library10.1007/s00281-020-00814-z
26.
Tang Y., Fung E., Xu A., Lan H.-Y. C-reactive protein and ageing. Clin. Exp. Pharmacol. Physiol. 2017;44:9-14.
Not in our library10.1111/1440-1681.12758
27.
Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines · 2018
No notice
28.
Marcos-Pérez D., Sánchez-Flores M., Proietti S., Bonassi S., Costa S., Teixeira J.P., Fernández-Tajes J., Pásaro E., Laffon B., Valdiglesias V. Association of inflammatory mediators with frailty status in older adults: Results from a systematic review and meta-analysis. GeroScience. 2020;42:1451-1473.
Not in our library10.1007/s11357-020-00247-4
29.
Tchalla A.E., Wellenius G.A., Travison T.G., Gagnon M., Iloputaife I., Dantoine T., Sorond F.A., Lipsitz L.A. Circulating Vascular Cell Adhesion Molecule-1 Is Associated With Cerebral Blood Flow Dysregulation, Mobility Impairment, and Falls in Older Adults. Hypertension. 2015;66:340-346.
Not in our library10.1161/hypertensionaha.115.05180
30.
Prochaska J.H., Frank B., Nagler M., Lamparter H., Weißer G., Schulz A., Eggebrecht L., Göbel S., Arnold N., Panova-Noeva M., et al. Age-related diagnostic value of D-dimer testing and the role of inflammation in patients with suspected deep vein thrombosis. Sci. Rep. 2017;7:1-10.
Not in our library10.1038/s41598-017-04843-x
31.
Lee S.-H., Lee J.-H., Lee H.-Y., Min A.K.-J. Sirtuin signaling in cellular senescence and aging. BMB Rep. 2019;52:24-34.
Not in our library10.5483/bmbrep.2019.52.1.290
32.
Franceschi C., Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. A Biol. Sci. Med. Sci. 2014;69:4-9.
Not in our library10.1093/gerona/glu057
33.
Kennedy B.K., Berger S.L., Brunet A., Campisi J., Cuervo A.M., Epel E.S., Franceschi C., Lithgow G.J., Morimoto R.I., Pessin J.E., et al. Geroscience: Linking Aging to Chronic Disease. Cell. 2014;159:709-713.
Not in our library10.1016/j.cell.2014.10.039
34.
Chen W.-W., Zhang X., Huang W.-J. Role of neuroinflammation in neurodegenerative diseases (Review). Mol. Med. Rep. 2016;13:3391-3396.
Not in our library10.3892/mmr.2016.4948
35.
Gross A.L., Walker K.A., Moghekar A.R., Pettigrew C., Soldan A., Albert M.S., Walston J.D. Plasma Markers of Inflammation Linked to Clinical Progression and Decline During Preclinical AD. Front. Aging Neurosci. 2019;11:229.
Not in our library10.3389/fnagi.2019.00229
36.
Kuo C.-Y., Stachiv I., Nikolai T. Association of Late Life Depression, (Non-) Modifiable Risk and Protective Factors with Dementia and Alzheimer’s Disease: Literature Review on Current Evidences, Preventive Interventions and Possible Future Trends in Prevention and Treatment of Dementia. Int. J. Environ. Res. Public Health. 2020;17:7475.
Not in our library10.3390/ijerph17207475
37.
Hou Y., Dan X., Babbar M., Wei Y., Hasselbalch S.G., Croteau D.L., Bohr V.A. Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol. 2019;15:565-581.
Not in our library10.1038/s41582-019-0244-7
38.
New approaches to symptomatic treatments for Alzheimer’s disease · 2021
Corrected
39.
Yiannopoulou K.G., Papageorgiou S.G. Current and future treatments for Alzheimer’s disease. Ther. Adv. Neurol. Disord. 2013;6:19-33.
Not in our library10.1177/1756285612461679
40.
The neuropathological diagnosis of Alzheimer’s disease · 2019
No notice
41.
Masters C.L., Bateman R., Blennow K., Rowe C.C., Sperling R.A., Cummings J.L. Alzheimer’s disease. Nat. Rev. Dis. Primers. 2015;1:15056.
Not in our library10.1038/nrdp.2015.56
42.
Roda A.R., Montoliu-Gaya L., Serra-Mir G., Villegas S. Both Amyloid-β Peptide and Tau Protein Are Affected by an Anti-Amyloid-β Antibody Fragment in Elderly 3xTg-AD Mice. Int. J. Mol. Sci. 2020;21:6630.
Not in our library10.3390/ijms21186630
43.
Reitz C., Rogaeva E., Beecham G.W. Late-onset vs nonmendelian early-onset Alzheimer disease: A distinction without a difference? Neurol. Genet. 2020;6:e512.
Not in our library10.1212/nxg.0000000000000512
44.
Reitz C., Mayeux R. Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol. 2014;88:640-651.
Not in our library10.1016/j.bcp.2013.12.024
45.
Cruchaga C., Del-Aguila J.L., Saef B., Black K., Fernandez M.V., Budde J., Ibanez L., Deming Y., Kapoor M., Tosto G., et al. Polygenic risk score of sporadic late-onset Alzheimer’s disease reveals a shared architecture with the familial and early-onset forms. Alzheimer’s Dement. 2018;14:205-214.
Not in our library10.1016/j.jalz.2017.08.013
46.
Kelleher R.J., Shen J. Presenilin-1 mutations and Alzheimer’s disease. Proc. Natl. Acad. Sci. USA. 2017;114:629-631.
Not in our library10.1073/pnas.1619574114
47.
A An S.S., Cai Y., Kim S. Mutations in presenilin 2 and its implications in Alzheimer’s disease and other dementia-associated disorders. Clin. Interv. Aging. 2015;10:1163-1172.
Not in our library10.2147/cia.s85808
48.
Tambini M.D., A Norris K., D’Adamio L. Opposite changes in APP processing and human Aβ levels in rats carrying either a protective or a pathogenic APP mutation. eLife. 2020;9:9.
Not in our library10.7554/elife.52612
49.
Vidal C., Zhang L. An Analysis of the Neurological and Molecular Alterations Underlying the Pathogenesis of Alzheimer’s Disease. Cells. 2021;10:546.
Not in our library10.3390/cells10030546
50.
Tang M., Ryman D.C., McDade E., Jasielec M.S., Buckles V.D., Cairns N.J., Faga A.M., Goate A., Marcus D.S., Xiong C., et al. Neurological manifestations of autosomal dominant familial Alzheimer’s disease: A comparison of the published literature with the dominantly inherited Alzheimer network observational study (DIAN-OBS). Lancet Neurol. 2016;15:1317-1325.
Not in our library10.1016/s1474-4422(16)30229-0
51.
The age factor in Alzheimer’s disease · 2015
No notice
52.
Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921-923.
Not in our library10.1126/science.8346443
53.
Naj A.C., Schellenberg G.D. Alzheimer’s Disease Genetics Consortium (ADGC). Genomic variants, genes, and pathways of Alzheimer’s disease: An overview. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2017;174:5-26.
Not in our library10.1002/ajmg.b.32499
54.
Prokopenko D., Morgan S.L., Mullin K., Hofmann O., Chapman B., Kirchner R., Amberkar S., Wohlers I., Lange C., Hide W., et al. Whole-genome sequencing reveals new Alzheimer’s disease–associated rare variants in loci related to synaptic function and neuronal development. Alzheimer’s Dement. 2021.
Not in our library10.1002/alz.12319
55.
Karch C.M., Goate A.M. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry. 2015;77:43-51.
Not in our library10.1016/j.biopsych.2014.05.006
56.
Grozeva D., Saad S., Menzies G.E., Sims R. Benefits and Challenges of Rare Genetic Variation in Alzheimer’s Disease. Curr. Genet. Med. Rep. 2019;7:53-62.
Not in our library10.1007/s40142-019-0161-5
57.
Lord J., Lu A.J., Cruchaga C. Identification of rare variants in Alzheimer’s disease. Front. Genet. 2014;5:369.
Not in our library10.3389/fgene.2014.00369
58.
Lambert J.C., Ibrahim-Verbaas C.A., Harold D., Naj A.C., Sims R., Bellenguez C., DeStafano A.L., Bis J.C., Beecham G.W., Grenier-Boley B., et al. Meta-Analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet. 2013;45:1452-1458.
Not in our library10.1038/ng.2802
59.
Sims R., van der Lee S.J., Naj A.C., Bellenguez C., Badarinarayan N., Jakobsdottir J., Kunkle B.W., Boland A., Raybould R., Bis J.C., et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nat. Genet. 2017;49:1373-1384.
Not in our library10.1038/ng.3916
60.
Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk · 2017
No notice
61.
New insights into the role of TREM2 in Alzheimer’s disease · 2018
No notice
62.
Shi Y., Holtzman D.M. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat. Rev. Immunol. 2018;18:759-772.
Not in our library10.1038/s41577-018-0051-1
63.
Klein H.-U., McCabe C., Gjoneska E., Sullivan S.E., Kaskow B.J., Tang A., Smith R.V., Xu J., Pfenning A.R., Bernstein B.E., et al. Epigenome-wide study uncovers large-scale changes in histone acetylation driven by tau pathology in aging and Alzheimer’s human brains. Nat. Neurosci. 2019;22:37-46.
Not in our library10.1038/s41593-018-0291-1
64.
Lin Y.T., Seo J., Gao F., Feldman H.M., Wen H.L., Penney J., Cam H.P., Gjoneska E., Raja W.K., Cheng J., et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types. Neuron. 2018;98:1141-1154.
Not in our library10.1016/j.neuron.2018.05.008
65.
Gambhir I., Misra A., Chakrabarti S. New genetic players in late-onset Alzheimer’s disease: Findings of genome-wide association studies. Indian J. Med Res. 2018;148:135-144.
Not in our library10.4103/ijmr.ijmr_473_17
66.
The amyloid hypothesis of Alzheimer's disease at 25 years · 2016
No notice
67.
Guerreiro R., Wojtas A., Bras J., Carrasquillo M.M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S.G., et al. TREM2 Variants in Alzheimer’s Disease. N. Engl. J. Med. 2013;368:117-127.
Not in our library10.1056/nejmoa1211851
68.
Li J.-T., Zhang Y. TREM2 regulates innate immunity in Alzheimer’s disease. J. Neuroinflamm. 2018;15.
Not in our library10.1186/s12974-018-1148-y
69.
Zheng H., Cheng B., Li Y., Li X., Chen X., Zhang Y.-W. TREM2 in Alzheimer’s Disease: Microglial Survival and Energy Metabolism. Front. Aging Neurosci. 2018;10:395.
Not in our library10.3389/fnagi.2018.00395
70.
Zhong L., Chen X.-F., Wang T., Wang Z., Liao C., Wang Z., Huang R., Wang D., Li X., Wu L., et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival. J. Exp. Med. 2017;214:597-607.
Not in our library10.1084/jem.20160844
71.
Hickman S.E., El Khoury J. TREM2 and the neuroimmunology of Alzheimer’s disease. Biochem. Pharmacol. 2014;88:495-498.
Not in our library10.1016/j.bcp.2013.11.021
72.
Gong C.-X., Liu F., Iqbal K. Multifactorial Hypothesis and Multi-Targets for Alzheimer’s Disease. J. Alzheimer’s Dis. 2018;64:S107-S117.
Not in our library10.3233/jad-179921
73.
The role of ABCA7 in Alzheimer’s disease: evidence from genomics, transcriptomics and methylomics · 2019
No notice
74.
Iqbal K., Grundke-Iqbal I. Alzheimer’s disease, a multifactorial disorder seeking multitherapies. Alzheimer's Dement. 2010;6:420-424.
Not in our library10.1016/j.jalz.2010.04.006
75.
Heppner F.L., Ransohoff R.M., Becher B. Immune attack: The role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 2015;16:358-372.
Not in our library10.1038/nrn3880
76.
Sala Frigerio C., Wolfs L., Fattorelli N., Thrupp N., Voytyuk I., Schmidt I., Mancuso R., Chen W.T., Woodbury M.E., Srivastava G., et al. The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques. Cell Rep. 2019;27:1293-1306.
Not in our library10.1016/j.celrep.2019.03.099
77.
Ising C., Venegas C., Zhang S., Scheiblich H., Schmidt S.V., Vieira-Saecker A., Schwartz S., Albasset S., McManus R.M., Tejera D., et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575:669-673.
Not in our library10.1038/s41586-019-1769-z
78.
Shen Z., Bao X., Wang R. Clinical PET Imaging of Microglial Activation: Implications for Microglial Therapeutics in Alzheimer’s Disease. Front. Aging Neurosci. 2018;10:314.
Not in our library10.3389/fnagi.2018.00314
79.
Yao K., Zu H.B. Microglial polarization: Novel therapeutic mechanism against Alzheimer’s disease. Inflammopharmacology. 2020;28:95-110.
Not in our library10.1007/s10787-019-00613-5
80.
Tondo G., Iaccarino L., Caminiti S.P., Presotto L., Santangelo R., Iannaccone S., Magnani G., Perani D. The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer’s disease. Alzheimer’s Res. Ther. 2020;12:1-10.
Not in our library10.1186/s13195-020-00619-0
81.
Wang W.-Y., Tan M.-S., Yu J.T., Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann. Transl. Med. 2015;3:136.
Not in our library10.3978/j.issn.2305-5839.2015.03.49
82.
Stamouli E.C., Politis A.M. Pro-inflammatory cytokines in Alzheimer’s disease. Psychiatriki. 2016;27:264-275.
Not in our library10.22365/jpsych.2016.274.264
83.
Wang M.-M., Miao D., Cao X.-P., Tan L., Tan L. Innate immune activation in Alzheimer’s disease. Ann. Transl. Med. 2018;6:177.
Not in our library10.21037/atm.2018.04.20
84.
Fernández-Arjona M.D.M., Grondona J.M., Fernández-Llebrez P., López-Ávalos M.D. Microglial Morphometric Parameters Correlate With the Expression Level of IL-1β, and Allow Identifying Different Activated Morphotypes. Front. Cell Neurosci. 2019;13:472.
Not in our library10.3389/fncel.2019.00472
85.
Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., et al. Inflammation and Alzheimer’s disease. Neurobiol. Aging. 2000;21:383-421.
Not in our library10.1016/s0197-4580(00)00124-x
86.
Azizi G., Navabi S.S., Al-Shukaili A., Seyedzadeh M.H., Yazdani R., Mirshafiey A. The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer’s Disease. Sultan Qaboos Univ. Med. J. 2015;15:e305-e316.
Not in our library10.18295/squmj.2015.15.03.002
87.
Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species · 2019
No notice
88.
Heneka M.T., Carson M.J., El Khoury J., Landreth G.E., Brosseron F., Feinstein D.L., Jacobs A.H., Wyss-Coray T., Vitorica J., Ransohoff R.M., et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388-405.
Not in our library10.1016/s1474-4422(15)70016-5
89.
Inflammatory process in Alzheimer's Disease · 2013
No notice
90.
Businaro R., Corsi M., Asprino R., Di Lorenzo C., Laskin D., Corbo R., Ricci S., Pinto A. Modulation of Inflammation as a Way of Delaying Alzheimer’s Disease Progression: The Diet’s Role. Curr. Alzheimer Res. 2018;15:363-380.
Not in our library10.2174/1567205014666170829100100
91.
An Inflammation-Centric View of Neurological Disease: Beyond the Neuron · 2018
Corrected
92.
Duran-Aniotz C., Hetz C. Glucose Metabolism: A Sweet Relief of Alzheimer’s Disease. Curr. Biol. 2016;26:R806-R809.
Not in our library10.1016/j.cub.2016.07.060
93.
Tönnies E., Trushina E. Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease. J. Alzheimer's Dis. 2017;57:1105-1121.
Not in our library10.3233/jad-161088
94.
Thal D.R., Capetillo-Zarate E., Larionov S., Staufenbiel M., Zurbruegg S., Beckmann N. Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiol. Aging. 2009;30:1936-1948.
Not in our library10.1016/j.neurobiolaging.2008.01.017
95.
Potter H., Granic A., Caneus J. Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer’s Disease. Curr. Alzheimer Res. 2015;13:7-17.
Not in our library10.2174/156720501301151207100616
96.
Clare R., King V.G., Wirenfeldt M., Vinters H.V. Synapse loss in dementias. J. Neurosci. Res. 2010;88:2083-2090.
Not in our library10.1002/jnr.22392
97.
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances · 2020
No notice
98.
Norris G.T., Kipnis J. Immune cells and CNS physiology: Microglia and beyond. J. Exp. Med. 2019;216:60-70.
Not in our library10.1084/jem.20180199
99.
Bennett M.L., Bennett F.C., Liddelow S.A., Ajami B., Zamanian J.L., Fernhoff N.B., Mulinyawe S.B., Bohlen C.J., Adil A., Tucker A., et al. New tools for studying microglia in the mouse and human CNS. Proc. Natl. Acad. Sci. USA. 2016;113:E1738-E1746.
Not in our library10.1073/pnas.1525528113
100.
Buttgereit A., Lelios I., Yu X., Vrohlings M., Krakoski N.R., Gautier E.L., Nishinakamura R., Becher B., Greter M. Sall1 is a transcriptional regulator defining microglia identity and function. Nat. Immunol. 2016;17:1397-1406.
Not in our library10.1038/ni.3585
101.
Gomez Perdiguero E., Klapproth K., Schulz C., Busch K., Azzoni E., Crozet L., Garner H., Trouillet C., de Bruijn M.F., Geissmann F., et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature. 2014;518:547-551.
Not in our library10.1038/nature13989
102.
Gosselin D., Link V.M., Romanoski C.E., Fonseca G.J., Eichenfield D.Z., Spann N.J., Stender J.D., Chun H.B., Garner H., Geissmann F., et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell. 2014;159:1327-1340.
Not in our library10.1016/j.cell.2014.11.023
103.
Sheng J., Ruedl C., Karjalainen K. Most tissue-resident macrophages except microglia are derived from fetal hematopoietic stem cells. Immunity. 2015;43:382-393.
Not in our library10.1016/j.immuni.2015.07.016
104.
Hoeffel G., Chen J., Lavin Y., Low D., Almeida F.F., See P., Beaudin A.E., Lum J., Low I., Forsberg E.C., et al. C-Myb+ erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity. 2015;42:665-678.
Not in our library10.1016/j.immuni.2015.03.011
105.
Ajami B., Bennett J.L., Krieger C., Tetzlaff W., Rossi F.M. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 2007;10:1538-1543.
Not in our library10.1038/nn2014
106.
Tay T.L., Hagemeyer N., Prinz M. The force awakens: Insights into the origin and formation of microglia. Curr. Opin. Neurobiol. 2016;39:30-37.
Not in our library10.1016/j.conb.2016.04.003
107.
Elmore M.R.P., Najafi A.R., Koike M.A., Dagher N.N., Spangenberg E.E., Rice R.A., Kitazawa M., Matusow B., Nguyen H., West B.L., et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82:380-397.
Not in our library10.1016/j.neuron.2014.02.040
108.
Microglia and Beyond: Innate Immune Cells As Regulators of Brain Development and Behavioral Function · 2018
No notice
109.
Mildner A., Schmidt H., Nitsche M., Merkler D., Hanisch U.-K., Mack M., Heikenwalder M., Brück W., Priller J., Prinz M., et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat. Neurosci. 2007;10:1544-1553.
Not in our library10.1038/nn2015
110.
Wohleb E.S., Powell N.D., Godbout J.P., Sheridan J.F. Stress-induced recruitment of bone marrow-derived monocytes to the brain promotes anxiety-like behavior. J. Neurosci. 2013;33:13820-13833.
Not in our library10.1523/jneurosci.1671-13.2013
111.
Inflammatory Response in the CNS: Friend or Foe? · 2016
No notice
112.
Tejera D., Heneka M.T. Microglia in Alzheimer’s disease: The good, the bad and the ugly. Curr. Alzheimer Res. 2016;13:370-380.
Not in our library10.2174/1567205013666151116125012
113.
Wyss-Coray T., Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harbor Perspect. Med. 2012;2:a006346.
Not in our library10.1101/cshperspect.a006346
114.
Biber K., Neumann H., Inoue K., Boddeke H.W.G.M. Neuronal ‘On’ and ‘Off’ signals control microglia. Trends Neurosci. 2007;30:596-602.
Not in our library10.1016/j.tins.2007.08.007
115.
Baroja-Mazo A., Martín-Sánchez F., Gomez A.I., Martínez C.M., Amores-Iniesta J., Compan V., Barberà-Cremades M., Yagüe J., Ruiz-Ortiz E., Antón J., et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat. Immunol. 2014;15:738-748.
Not in our library10.1038/ni.2919
116.
Koenigsknecht-Talboo J., Landreth G.E. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 2005;25:8240-8249.
Not in our library10.1523/jneurosci.1808-05.2005
117.
Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia · 2009
No notice
118.
Hommet C., Mondon K., Camus V., Ribeiro M.J., Beaufils E., Arlicot N., Corcia P., Paccalin M., Minier F., Gosselin T., et al. Neuroinflammation and β Amyloid Deposition in Alzheimer’s Disease: In vivo Quantification with Molecular Imaging. Dement. Geriatr. Cogn. Disord. 2014;37:1-18.
Not in our library10.1159/000354363
119.
Nagele R.G., Wegiel J., Venkataraman V., Imaki H., Wang K.C., Wegiel J. Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease. Neurobiol. Aging. 2004;25:663-674.
Not in our library10.1016/j.neurobiolaging.2004.01.007
120.
Serrano-Pozo A., Mielke M.L., Gómez-Isla T., Betensky R.A., Growdon J.H., Frosch M.P., Hyman B.T. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am. J. Pathol. 2020;179:1373-1384.
Not in our library10.1016/j.ajpath.2011.05.047
121.
Minter M.R., Taylor J.M., Crack P.J. The contribution of neuroinflammation to amyloid toxicity in Alzheimer’s disease. J. Neurochem. 2016;136:457-474.
Not in our library10.1111/jnc.13411
122.
Bamberger M.E., Harris M.E., McDonald D.R., Husemann J., Landreth G.E. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J. Neurosci. 2003;23:2665-2674.
Not in our library10.1523/jneurosci.23-07-02665.2003
123.
Mechanisms of Aβ Clearance and Degradation by Glial Cells · 2016
No notice
124.
Tahara K., Kim H.-D., Jin J.-J., Maxwell J.A., Li L., Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain J. Neurol. 2006;129:3006-3019.
Not in our library10.1093/brain/awl249
125.
Microglial Scavenger Receptors and Their Roles in the Pathogenesis of Alzheimer's Disease · 2012
No notice
126.
Hickman S.E., Allison E.K., El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice. J. Neurosci. 2008;28:8354-8360.
Not in our library10.1523/jneurosci.0616-08.2008
127.
The dynamics of monocytes and microglia in Alzheimer’s disease · 2015
No notice
128.
Weiner H.L., Frenkel D. Immunology and immunotherapy of Alzheimer’s disease. Nat. Rev. Immunol. 2006;6:404-416.
Not in our library10.1038/nri1843
129.
Frackowiak J., Wisniewski H.M., Wegiel J., Merz G.S., Iqbal K., Wang K.C. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol. 1992;84:225-233.
Not in our library10.1007/bf00227813
130.
Functional Impairment of Microglia Coincides with Beta-Amyloid Deposition in Mice with Alzheimer-Like Pathology · 2013
No notice
131.
Nagele R.G., D’Andrea M.R., Lee H., Venkataraman V., Wang H.Y. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 2003;971:197-209.
Not in our library10.1016/s0006-8993(03)02361-8
132.
Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O’Banion K., Klockgether T., Van Leuven F., Landreth G.E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain. 2005;128:1442-1453.
Not in our library10.1093/brain/awh452
133.
Meda L., Baron P., Scarlato G. Glial activation in Alzheimer’s disease: The role of Abeta and its associated proteins. Neurobiol. Aging. 2001;22:885-893.
Not in our library10.1016/s0197-4580(01)00307-4
134.
Morgan D., Gordon M.N., Tan J., Wilcock D., Rojiani A.M. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: Implications for Alzheimer therapeutics. J. Neuropathol. Exp. Neurol. 2005;64:743-753.
Not in our library10.1097/01.jnen.0000178444.33972.e0
135.
Tuppo E.E., Arias H.R. The role of inflammation in Alzheimer’s disease. Int. J. Biochem. Cell Biol. 2005;37:289-305.
Not in our library10.1016/j.biocel.2004.07.009
136.
Tan Z.S., Seshadri S. Inflammation in the Alzheimer’s disease cascade: Culprit or innocent bystander? Alzheimer's Res. Ther. 2010;2:6.
Not in our library10.1186/alzrt29
137.
Joshi P.G., Turola E., Ruiz A., Bergami A., Libera D.D., Benussi L., Giussani P., Magnani G., Comi G., Legname G., et al. Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles. Cell Death Differ. 2014;21:582-593.
Not in our library10.1038/cdd.2013.180
138.
Hansen D.V., Hanson J.E., Sheng M. Microglia in Alzheimer’s disease. J. Cell Biol. 2018;217:459-472.
Not in our library10.1083/jcb.201709069
139.
Jiang C., Zou X., Zhu R., Shi Y., Wu Z., Zhao F., Chen L. The correlation between accumulation of amyloid beta with enhanced neuroinflammation and cognitive impairment after intraventricular hemorrhage. J. Neurosurg. 2018;131:54-63.
Not in our library10.3171/2018.1.jns172938
140.
Edison P., Archer H.A., Gerhard A., Hinz R., Pavese N., Turkheimer F.E., Hammers A., Tai Y.F., Fox N., Kennedy A., et al. Microglia, amyloid, and cognition in Alzheimer’s disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol. Dis. 2008;32:412-419.
Not in our library10.1016/j.nbd.2008.08.001
141.
Okello A., Edison P., Archer H.A., Turkheimer F., Kennedy J., Bullock R., Walker Z., Fox N., Rossor M., Brooks D.J. Microglial activation and amyloid deposition in mild cognitive impairment: A PET study. Neurology. 2009;72:56-62.
Not in our library10.1212/01.wnl.0000338622.27876.0d
142.
Hamelin L., Lagarde J., Dorothée G., Leroy C., Labit M., Comley R.A., De Souza L.C., Corne H., Dauphinot L., Bertoux M., et al. Early and protective microglial activation in Alzheimer’s disease: A prospective study using18F-DPA-714 PET imaging. Brain. 2016;139:1252-1264.
Not in our library10.1093/brain/aww017
143.
Fan Z., Okello A.A., Brooks D.J., Edison P. Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer’s disease. Brain. 2015;138:3685-3698.
Not in our library10.1093/brain/awv288
144.
Yokokura M., Mori N., Yagi S., Yoshikawa E., Kikuchi M., Yoshihara Y., Wakuda T., Sugihara G., Takebayashi K., Suda S., et al. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging. 2010;38:343-351.
Not in our library10.1007/s00259-010-1612-0
145.
Gosztyla M.L., Brothers H.M., Robinson S.R. Alzheimer’s Amyloid-β is an Antimicrobial Peptide: A Review of the Evidence. J. Alzheimer's Dis. 2018;62:1495-1506.
Not in our library10.3233/jad-171133
146.
Chung W.-S., Allen N.J., Eroglu C. Astrocytes Control Synapse Formation, Function, and Elimination. Cold Spring Harb. Perspect. Biol. 2015;7:a020370.
Not in our library10.1101/cshperspect.a020370
147.
Verkhratsky A., Nedergaard M. Physiology of Astroglia. Physiol. Rev. 2018;98:239-389.
Not in our library10.1152/physrev.00042.2016
148.
Astrocytes in Alzheimer’s Disease: Pathological Significance and Molecular Pathways · 2021
No notice
149.
Sheeler C., Rosa J.-G., Ferro A., McAdams B., Borgenheimer E., Cvetanovic M. Glia in Neurodegeneration: The Housekeeper, the Defender and the Perpetrator. Int. J. Mol. Sci. 2020;21:9188.
Not in our library10.3390/ijms21239188
150.
Gamage R., Wagnon I., Rossetti I., Childs R., Niedermayer G., Chesworth R., Gyengesi E. Cholinergic Modulation of Glial Function During Aging and Chronic Neuroinflammation. Front. Cell. Neurosci. 2020;14:577912.
Not in our library10.3389/fncel.2020.577912
151.
Linnerbauer M., Wheeler M.A., Quintana F.J. Astrocyte Crosstalk in CNS Inflammation. Neuron. 2020;108:608-622.
Not in our library10.1016/j.neuron.2020.08.012
152.
Giovannoni F., Quintana F.J. The role of astrocytes in CNS inflammation. Trends Immunol. 2020;41:805-819.
Not in our library10.1016/j.it.2020.07.007
153.
Hol E.M., Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr. Opin. Cell Biol. 2015;32:121-130.
Not in our library10.1016/j.ceb.2015.02.004
154.
Yang Z., Wang K.K. Glial fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38:364-374.
Not in our library10.1016/j.tins.2015.04.003
155.
Beach T., McGeer E. Lamina-specific arrangement of astrocytic gliosis and senile plaques in Alzheimer’s disease visual cortex. Brain Res. 1988;463:357-361.
Not in our library10.1016/0006-8993(88)90410-6
156.
Rodríguez J.J., Olabarria M., Chvatal A., Verkhratsky A., Rodr J.J. Astroglia in dementia and Alzheimer’s disease. Cell Death Differ. 2008;16:378-385.
Not in our library10.1038/cdd.2008.172
157.
Verkhratsky A., Zorec R., Parpura V. Stratification of astrocytes in healthy and diseased brain. Brain Pathol. 2017;27:629-644.
Not in our library10.1111/bpa.12537
158.
Involvement of Astrocytes in Alzheimer’s Disease from a Neuroinflammatory and Oxidative Stress Perspective · 2017
No notice
159.
Colombo J., Quinn B., Puissant V. Disruption of astroglial interlaminar processes in Alzheimer’s disease. Brain Res. Bull. 2002;58:235-242.
Not in our library10.1016/s0361-9230(02)00785-2
160.
Yeh C.-Y., Vadhwana B., Verkhratsky A., Rodriguez J.J. Early Astrocytic Atrophy in the Entorhinal Cortex of a Triple Transgenic Animal Model of Alzheimer’s Disease. ASN Neuro. 2011;3:e00071.
Not in our library10.1042/an20110025
161.
Beauquis J., Vinuesa A., Pomilio C., Pavía P., Galván V., Saravia F. Neuronal and Glial Alterations, Increased Anxiety, and Cognitive Impairment before Hippocampal Amyloid Deposition in PDAPP Mice, Model of Alzheimer’s Disease. Hippocampus. 2014;24:257-269.
Not in our library10.1002/hipo.22219
162.
Diniz L.P., Tortelli V., Matias I., Morgado J., Araujo A.P.B., Melo H.M., Da Silva G.S.S., Alves-Leon S.V., De Souza J.M., Ferreira S.T., et al. Astrocyte Transforming Growth Factor Beta 1 Protects Synapses against Aβ Oligomers in Alzheimer’s Disease Model. J. Neurosci. 2017;37:6797-6809.
Not in our library10.1523/jneurosci.3351-16.2017
163.
Iram T., Trudler D., Kain D., Kanner S., Galron R., Vassar R., Barzilai A., Blinder P., Fishelson Z., Frenkel D. Astrocytes from old Alzheimer’s disease mice are impaired in Aβ uptake and in neuroprotection. Neurobiol. Dis. 2016;96:84-94.
Not in our library10.1016/j.nbd.2016.08.001
164.
Polis B., Srikanth K.D., Elliott E., Gil-Henn H., Samson A.O. L-Norvaline Reverses Cognitive Decline and Synaptic Loss in a Murine Model of Alzheimer’s Disease. Neurotherapeutics. 2018;15:1036-1054.
Not in our library10.1007/s13311-018-0669-5
165.
Aberrant iPSC-derived human astrocytes in Alzheimer's disease · 2017
Corrected
166.
Kraft A.W., Hu X., Yoon H., Yan P., Xiao Q., Wang Y., Gil S.C., Brown J., Wilhelmsson U., Restivo J.L., et al. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J. 2013;27:187-198.
Not in our library10.1096/fj.12-208660
167.
Kobayashi E., Nakano M., Kubota K., Himuro N., Mizoguchi S., Chikenji T., Otani M., Mizue Y., Nagaishi K., Fujimiya M. Activated forms of astrocytes with higher GLT-1 expression are associated with cognitive normal subjects with Alzheimer pathology in human brain. Sci. Rep. 2018;8:1-12.
Not in our library10.1038/s41598-018-19442-7
168.
Masliah E., Alford M., DeTeresa R., Mallory M., Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer’s disease. Ann. Neurol. 1996;40:759-766.
Not in our library10.1002/ana.410400512
169.
Scimemi A., Meabon J.S., Woltjer R.L., Sullivan J.M., Diamond J.S., Cook D.G. Amyloid-β1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. J. Neurosci. 2013;33:5312-5318.
Not in our library10.1523/jneurosci.5274-12.2013
170.
Vincent A.J., Gasperini R., Foa L., Small D.H. Astrocytes in Alzheimer’s Disease: Emerging Roles in Calcium Dysregulation and Synaptic Plasticity. J. Alzheimer’s Dis. 2010;22:699-714.
Not in our library10.3233/jad-2010-101089
171.
Oligodendroglia and Myelin in Neurodegenerative Diseases: More Than Just Bystanders? · 2015
No notice
172.
Mathys H., Davila-Velderrain J., Peng Z., Gao F., Mohammadi S., Young J.Z., Menon M., He L., Abdurrob F., Jiang X., et al. Single-cell transcriptomic analysis of Alzheimer’s disease. Nature. 2019;570:332-337.
Not in our library10.1038/s41586-019-1195-2
173.
Bartzokis G. Age-related myelin breakdown: A developmental model of cognitive decline and Alzheimer’s disease. Neurobiol. Aging. 2004;25:5-18.
Not in our library10.1016/j.neurobiolaging.2003.03.001
174.
Bartzokis G., Lu P.H., Mintz J. Quantifying age-related myelin breakdown with MRI: Novel therapeutic targets for preventing cognitive decline and Alzheimer’s disease. J. Alzheimer's Dis. 2004;6:S53-S59.
Not in our library10.3233/jad-2004-6s604
175.
Mitew S., Kirkcaldie M.T.K., Halliday G.M., Shepherd C.E., Vickers J.C., Dickson T.C. Focal demyelination in Alzheimer’s disease and transgenic mouse models. Acta Neuropathol. 2010;119:567-577.
Not in our library10.1007/s00401-010-0657-2
176.
Desai M.K., Mastrangelo M.A., Ryan D.A., Sudol K.L., Narrow W.C., Bowers W.J. Early Oligodendrocyte/Myelin Pathology in Alzheimer’s Disease Mice Constitutes a Novel Therapeutic Target. Am. J. Pathol. 2010;177:1422-1435.
Not in our library10.2353/ajpath.2010.100087
177.
Goldmann T., Wieghofer P., Jordão M.J.C., Prutek F., Hagemeyer N., Frenzel K., Amann L., Staszewski O., Kierdorf K., Krueger M., et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat. Immunol. 2016;17:797-805.
Not in our library10.1038/ni.3423
178.
Chinnery H.R., Ruitenberg M.J., McMenamin P.G. Novel characterization of monocyte-derived cell populations in the meninges and choroid plexus and their rates of replenishment in bone marrow chimeric mice. J. Neuropathol. Exp. Neurol. 2010;69:896-909.
Not in our library10.1097/nen.0b013e3181edbc1a
179.
Prinz M., Priller J. Microglia and brain macrophages in the molecular age: From origin to neuropsychiatric disease. Nat. Rev. Neurosci. 2014;15:300-312.
Not in our library10.1038/nrn3722
180.
Mohamed A., Posse de Chaves E. Aβ internalization by neurons and glia. Int. J. Alzheimer's Dis. 2011;2011:127984.
Not in our library10.4061/2011/127984
181.
Simard A.R., Soulet D., Gowing G., Julien J.-P., Rivest S. Bone Marrow-Derived Microglia Play a Critical Role in Restricting Senile Plaque Formation in Alzheimer’s Disease. Neuron. 2006;49:489-502.
Not in our library10.1016/j.neuron.2006.01.022
182.
Thanopoulou K., Fragkouli A., Stylianopoulou F., Georgopoulos S. Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model. Proc. Natl. Acad. Sci. USA. 2010;107:20816-20821.
Not in our library10.1073/pnas.1005888107
183.
Town T., Laouar Y., Pittenger C., Mori T., Szekely C.A., Tan J., Duman R.S., Flavell R.A. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 2008;14:681-687.
Not in our library10.1038/nm1781
184.
El Khoury J., Toft M., Hickman S.E., Means T.K., Terada K., Geula C., Luster A.D. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 2007;13:432-438.
Not in our library10.1038/nm1555
185.
Anding A.L., Baehrecke E.H. Cleaning House: Selective Autophagy of Organelles. Dev. Cell. 2017;41:10-22.
Not in our library10.1016/j.devcel.2017.02.016
186.
Selective autophagy of intracellular organelles: Recent research advances · 2021
No notice
187.
Wang R., Wang G. Autophagy in Mitochondrial Quality Control. Adv. Exp. Med. Biol. 2019;1206:421-434.
Not in our library10.1007/978-981-15-0602-4_19
188.
Harper J.W., Ordureau A., Heo J.-M. Building and decoding ubiquitin chains for mitophagy. Nat. Rev. Mol. Cell Biol. 2018;19:93-108.
Not in our library10.1038/nrm.2017.129
189.
Green D.R., Galluzzi L., Kroemer G. Mitochondria and the Autophagy-Inflammation-Cell Death Axis in Organismal Aging. Science. 2011;333:1109-1112.
Not in our library10.1126/science.1201940
190.
Green D.R., Levine B. To be or not to be? How selective autophagy and cell death govern cell fate. Cell. Mol. Life Sci. 2014;157:65-75.
Not in our library10.1016/j.cell.2014.02.049
191.
Desai S., Juncker M., Kim C. Regulation of mitophagy by the ubiquitin pathway in neurodegenerative diseases. Exp. Biol. Med. 2018;243:554-562.
Not in our library10.1177/1535370217752351
192.
Madruga E., Maestro I., Martínez A. Mitophagy Modulation, a New Player in the Race against ALS. Int. J. Mol. Sci. 2021;22:740.
Not in our library10.3390/ijms22020740
193.
Nakahira K., Haspel J.A., Rathinam V.A., Lee S.-J., Dolinay T., Lam H.C., Englert J.A., Rabinovitch M., Cernadas M., Kim H.P., et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 2011;12:222-230.
Not in our library10.1038/ni.1980
194.
Shimada K., Crother T.R., Karlin J., Dagvadorj J., Chiba N., Chen S., Ramanujan V.K., Wolf A.J., Vergnes L., Ojcius D.M., et al. Oxidized Mitochondrial DNA Activates the NLRP3 Inflammasome during Apoptosis. Immunity. 2012;36:401-414.
Not in our library10.1016/j.immuni.2012.01.009
195.
Dall’Olio F., Vanhooren V., Chen C.C., Slagboom P.E., Wuhrer M., Franceschi C. N-glycomic biomarkers of biological aging and longevity: A link with inflammaging. Ageing Res. Rev. 2013;12:685-698.
Not in our library10.1016/j.arr.2012.02.002
196.
Feldman N., Rotter-Maskowitz A., Okun E. DAMPs as mediators of sterile inflammation in aging-related pathologies. Ageing Res. Rev. 2015;24:29-39.
Not in our library10.1016/j.arr.2015.01.003
197.
Mitochondrial DNA in the regulation of innate immune responses · 2015
No notice
198.
Lamkanfi M., Dixit V.M. Mechanisms and functions of inflammasomes. Cell. 2014;157:1013-1022.
Not in our library10.1016/j.cell.2014.04.007
199.
Vanaja S.K., Rathinam V.A., Fitzgerald K.A. Mechanisms of inflammasome activation: Recent advances and novel insights. Trends Cell Biol. 2015;25:308-315.
Not in our library10.1016/j.tcb.2014.12.009
200.
Mamik M.K., Power C. Inflammasomes in neurological diseases: Emerging pathogenic and therapeutic concepts. Brain. 2017;140:2273-2285.
Not in our library10.1093/brain/awx133
201.
Swanson K.V., Deng M., Ting J.P.-Y. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 2019;19:477-489.
Not in our library10.1038/s41577-019-0165-0
202.
Downs K.P., Nguyen H., Dorfleutner A., Stehlik C. An overview of the non-canonical inflammasome. Mol. Asp. Med. 2020;76:100924.
Not in our library10.1016/j.mam.2020.100924
203.
Horng T. Calcium signaling and mitochondrial destabilization in the triggering of the NLRP3 inflammasome. Trends Immunol. 2014;35:253-261.
Not in our library10.1016/j.it.2014.02.007
204.
Harris J., Hartman M., Roche C., Zeng S.G., O’Shea A., Sharp F.A., Lambe E.M., Creagh E.M., Golenbock D.T., Tschopp J., et al. Autophagy controls IL-1{beta} secretion by targeting pro-IL-1{beta} for degradation. J. Biol. Chem. 2011;286:9587-9597.
Not in our library10.1074/jbc.m110.202911
205.
Lee C., Kim K.H., Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free. Radic. Biol. Med. 2016;100:182-187.
Not in our library10.1016/j.freeradbiomed.2016.05.015
206.
Zhai D., Ye Z., Jiang Y., Xu C., Ruan B., Yang Y., Lei X., Xiang A., Lu H., Zhu Z., et al. MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA. Mol. Immunol. 2017;92:151-160.
Not in our library10.1016/j.molimm.2017.10.017
207.
Oh Y.K., Bachar A.R., Zacharias D.G., Kim S.G., Wan J., Cobb L.J., Lerman L.O., Cohen P., Lerman A. Humanin preserves endothelial function and prevents atherosclerotic plaque progression in hypercholesterolemic ApoE deficient mice. Atherosclerosis. 2011;219:65-73.
Not in our library10.1016/j.atherosclerosis.2011.06.038
208.
Sreekumar P.G., Ishikawa K., Spee C., Mehta H.H., Wan J., Yen K., Cohen P., Kannan R., Hinton D.R. The Mitochondrial-Derived Peptide Humanin Protects RPE Cells From Oxidative Stress, Senescence, and Mitochondrial Dysfunction. Investig. Opthalmology Vis. Sci. 2016;57:1238-1253.
Not in our library10.1167/iovs.15-17053
209.
Humanin: A Novel Central Regulator of Peripheral Insulin Action · 2009
No notice
210.
Halle A., Hornung V., Petzold G.C., Stewart C.R., Monks B.G., Reinheckel T., Fitzgerald K.A., Latz E., Moore K.J., Golenbock D.T. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 2008;9:857-865.
Not in our library10.1038/ni.1636
211.
Heneka M.T., Golenbock D.T., Latz E. Innate immunity in Alzheimer’s disease. Nat. Immunol. 2015;16:229-236.
Not in our library10.1038/ni.3102
212.
Kim M.-J., Yoon J.-H., Ryu J.-H. Mitophagy: A balance regulator of NLRP3 inflammasome activation. BMB Rep. 2016;49:529-535.
Not in our library10.5483/bmbrep.2016.49.10.115
213.
Joshi A.U., Minhas P.S., Liddelow S.A., Haileselassie B., Andreasson K.I., Dorn G.W., Mochly-Rosen D. Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration. Nat. Neurosci. 2019;22:1635-1648.
Not in our library10.1038/s41593-019-0486-0
214.
Fairley L.H., Wong J.H., Barron A.M. Mitochondrial Regulation of Microglial Immunometabolism in Alzheimer’s Disease. Front. Immunol. 2021;12:12.
Not in our library10.3389/fimmu.2021.624538
215.
Old Maids: Aging and Its Impact on Microglia Function · 2017
No notice
216.
Mitochondrial Dysfunction and Alzheimer’s Disease: Role of Microglia · 2020
No notice
217.
Baik S.H., Kang S., Lee W., Choi H., Chung S., Kim J.-I., Mook-Jung I. A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer’s Disease. Cell Metab. 2019;30:493-507.e6.
Not in our library10.1016/j.cmet.2019.06.005
218.
Metabolic Regulation of Glial Phenotypes: Implications in Neuron–Glia Interactions and Neurological Disorders · 2020
Not checked
219.
Metabolic Reprograming of Microglia in the Regulation of the Innate Inflammatory Response · 2020
No notice
220.
Afridi R., Lee W.H., Suk K. Microglia Gone Awry: Linking Immunometabolism to Neurodegeneration. Front. Cell Neurosci. 2020;14:246.
Not in our library10.3389/fncel.2020.00246
221.
Pan R.Y., Ma J., Kong X.X., Wang X.F., Li S.S., Qi X.L., Yan Y.H., Cheng J., Liu Q., Jin W., et al. Sodium rutin ameliorates Alzheimer’s disease-like pathology by enhancing microglial amyloid-β clearance. Sci. Adv. 2019;5:eaau6328.
Not in our library10.1126/sciadv.aau6328
222.
Bonda D.J., Wang X., Lee H.-G., Smith M.A., Perry G., Zhu X. Neuronal failure in Alzheimer’s disease: A view through the oxidative stress looking-glass. Neurosci. Bull. 2014;30:243-252.
Not in our library10.1007/s12264-013-1424-x
223.
Dorey E., Chang N., Liu Q.Y., Yang Z., Zhang W. Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer’s disease. Neurosci. Bull. 2014;30:317-330.
Not in our library10.1007/s12264-013-1422-z
224.
Giasson B.I., Duda J.E., Murray I.V.J., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M.Y. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science. 2000;290:985-989.
Not in our library10.1126/science.290.5493.985
225.
Interrelation of Oxidative Stress and Inflammation in Neurodegenerative Disease: Role of TNF · 2015
No notice
226.
Cheeseman K.H., Slater T.F. An Introduction to Free-Radical Biochemistry. Br. Med. Bull. 1993;49:481-493.
Not in our library10.1093/oxfordjournals.bmb.a072625
227.
Marosi K., Bori Z., Hart N., Sárga L., Koltai E., Radák Z., Nyakas C. Long-term exercise treatment reduces oxidative stress in the hippocampus of aging rats. Neurosci. 2012;226:21-28.
Not in our library10.1016/j.neuroscience.2012.09.001
228.
Liguori I., Russo G., Curcio F., Bulli G., Aran L., Della-Morte D., Gargiulo G., Testa G., Cacciatore F., Bonaduce D., et al. Oxidative stress, aging, and diseases. Clin. Interv. Aging. 2018;ume 13:757-772.
Not in our library10.2147/cia.s158513
229.
Baeeri M., Bahadar H., Rahimifard M., Navaei-Nigjeh M., Khorasani R., Rezvanfar M.A., Gholami M., Abdollahi M. Alpha-Lipoic acid prevents senescence, cell cycle arrest, and inflammatory cues in fibroblasts by inhibiting oxidative stress. Pharm. Res. 2019;141:214-223.
Not in our library10.1016/j.phrs.2019.01.003
230.
Chausse B., Lewen A., Poschet G., Kann O. Selective inhibition of mitochondrial respiratory complexes controls the transition of microglia into a neurotoxic phenotype in situ. Brain, Behav. Immun. 2020;88:802-814.
Not in our library10.1016/j.bbi.2020.05.052
231.
Calvani R., Picca A., Marini F., Biancolillo A., Gervasoni J., Persichilli S., Primiano A., Coelho-Junior H.J., Bossola M., Urbani A., et al. A Distinct Pattern of Circulating Amino Acids Characterizes Older Persons with Physical Frailty and Sarcopenia: Results from the BIOSPHERE Study. Nutrients. 2018;10:1691.
Not in our library10.3390/nu10111691
232.
Disabato D.J., Quan N., Godbout J.P. Neuroinflammation: The devil is in the details. J. Neurochem. 2016;139:136-153.
Not in our library10.1111/jnc.13607
233.
Relationship between Inflammation and Oxidative Stress and Cognitive Decline in the Institutionalized Elderly · 2015
No notice
234.
Zuo L., Christofi F.L., Wright V.P., Bao S., Clanton T.L. Lipoxygenase-dependent superoxide release in skeletal muscle. J. Appl. Physiol. 2004;97:661-668.
Not in our library10.1152/japplphysiol.00096.2004
235.
De la Fuente M., Miquel J. An update of the oxidation-inflammation theory of aging: The involvement of the immune system in oxi-inflamm-aging. Curr. Pharm. Des. 2009;15:3003-3026.
Not in our library10.2174/138161209789058110
236.
Daulatzai M.A. Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer’s disease. J. Neurosci. Res. 2017;95:943-972.
Not in our library10.1002/jnr.23777
237.
Campisi J., D’Adda Di Fagagna F. Cellular senescence: When bad things happen to good cells. Nat. Rev. Mol. Cell. Biol. 2007;8:729-740.
Not in our library10.1038/nrm2233
238.
Sharpless N.E., Sherr C.J. Forging a signature of in vivo senescence. Nat. Rev. Cancer. 2017;15:397-408.
Not in our library10.3410/f.725601274.793531867
239.
The Senescence-Associated Secretory Phenotype (SASP) in the Challenging Future of Cancer Therapy and Age-Related Diseases · 2020
No notice
240.
Acosta J.C., O’Loghlen A., Banito A., Guijarro M.V., Augert A., Raguz S., Fumagalli M., Da Costa M., Brown C., Popov N., et al. Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence. Cell. 2008;133:1006-1018.
Not in our library10.1016/j.cell.2008.03.038
241.
Coppé J.-P., Desprez P.-Y., Krtolica A., Campisi J. The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression. Annu. Rev. Pathol. Mech. Dis. 2010;5:99-118.
Not in our library10.1146/annurev-pathol-121808-102144
242.
Neves J., Demaria M., Campisi J., Jasper H. Of Flies, Mice, and Men: Evolutionarily Conserved Tissue Damage Responses and Aging. Dev. Cell. 2015;32:9-18.
Not in our library10.1016/j.devcel.2014.11.028
243.
“Social Life” of Senescent Cells: What Is SASP and Why Study It? · 2018
No notice
244.
Cortical neurons develop a senescence-like phenotype promoted by dysfunctional autophagy · 2019
No notice
245.
Acklin S., Zhang M., Du W., Zhao X., Plotkin M., Chang J., Campisi J., Zhou D., Xia F. Depletion of senescent-like neuronal cells alleviates cisplatin-induced peripheral neuropathy in mice. Sci. Rep. 2020;10:1-11.
Not in our library10.1038/s41598-020-71042-6
246.
Schmeer C., Kretz A., Wengerodt D., Stojiljkovic M., Witte O.W. Dissecting Aging and Senescence—Current Concepts and Open Lessons. Cells. 2019;8:1446.
Not in our library10.3390/cells8111446
247.
McHugh D., Gil J. Senescence and aging: Causes, consequences, and therapeutic avenues. J. Cell Biol. 2018;217:65-77.
Not in our library10.1083/jcb.201708092
248.
Wengerodt D., Schmeer C., Witte O.W., Kretz A. Amitosenescence and Pseudomitosenescence: Putative New Players in the Aging Process. Cells. 2019;8:1546.
Not in our library10.3390/cells8121546
249.
Bussian T.J., Aziz A., Meyer C.F., Swenson B.L., Van Deursen J.M., Baker D.J. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nat. Cell Biol. 2018;562:578-582.
Not in our library10.1038/s41586-018-0543-y
250.
Tau protein aggregation is associated with cellular senescence in the brain · 2018
No notice
251.
Walton C.C., Andersen J.K. Unknown fates of (brain) oxidation or UFO: Close encounters with neuronal senescence. Free Radic. Biol. Med. 2019;134:695-701.
Not in our library10.1016/j.freeradbiomed.2019.01.012
252.
Zhang P., Kishimoto Y., Grammatikakis I., Gottimukkala K., Cutler R.G., Zhang S., Abdelmohsen K., Bohr V.A., Sen J.M., Gorospe M., et al. Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model. Nat. Neurosci. 2019;22:719-728.
Not in our library10.1038/s41593-019-0372-9
253.
A proteomic atlas of senescence-associated secretomes for aging biomarker development · 2020
No notice
254.
Hernandez-Segura A., de Jong T.V., Melov S., Guryev V., Campisi J., Demaria M. Unmasking transcriptional heterogeneity in senescent cells. Curr. Biol. 2017;27:2652-2660.e4.
Not in our library10.1016/j.cub.2017.07.033
255.
Fafián-Labora J.A., O’Loghlen A. Classical and Nonclassical Intercellular Communication in Senescence and Ageing. Trends Cell Biol. 2020;30:628-639.
Not in our library10.1016/j.tcb.2020.05.003
256.
Herranz N., Gil J. Mechanisms and functions of cellular senescence. J. Clin. Investig. 2018;128:1238-1246.
Not in our library10.1172/jci95148
257.
Immune Clearance of Senescent Cells to Combat Ageing and Chronic Diseases · 2020
No notice
258.
Prata L.G.L., Ovsyannikova I.G., Tchkonia T., Kirkland J.L. Senescent cell clearance by the immune system: Emerging therapeutic opportunities. Semin. Immunol. 2018;40:101275.
Not in our library10.1016/j.smim.2019.04.003
259.
Ferrucci L., Fabbri E. Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty. Nat. Rev. Cardiol. 2018;15:505-522.
Not in our library10.1038/s41569-018-0064-2
260.
Demirci D., Dayanc B., Mazi F., Senturk S. The Jekyll and Hyde of Cellular Senescence in Cancer. Cells. 2021;10:208.
Not in our library10.3390/cells10020208
261.
Walton C.C., Begelman D., Nguyen W., Andersen J.K. Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis. Front. Cell. Neurosci. 2020;14:14.
Not in our library10.3389/fncel.2020.00129
262.
Carreno G., Guiho R., Martinez-Barbera J.P. Cell senescence in neuropathology: A focus on neurodegeneration and tumours. Neuropathol. Appl. Neurobiol. 2021;47:359-378.
Not in our library10.1111/nan.12689
263.
Astrocyte Senescence as a Component of Alzheimer’s Disease · 2012
No notice
264.
Pertusa M., García-Matas S., Rodríguez-Farré E., Sanfeliu C., Cristòfol R. Astrocytes aged in vitro show a decreased neuroprotective capacity. J. Neurochem. 2007;101:794-805.
Not in our library10.1111/j.1471-4159.2006.04369.x
265.
Mansour H., Chamberlain C.G., Weible M.W.I., Hughes S., Chu Y., Chan-Ling T. Aging-related changes in astrocytes in the rat retina: Imbalance between cell proliferation and cell death reduces astrocyte availability. Aging Cell. 2008;7:526-540.
Not in our library10.1111/j.1474-9726.2008.00402.x
266.
Lee J.-H., Yu W.H., Kumar A., Lee S., Mohan P.S., Peterhoff C.M., Wolfe D.M., Martinez-Vicente M., Massey A.C., Sovak G., et al. Lysosomal Proteolysis and Autophagy Require Presenilin 1 and Are Disrupted by Alzheimer-Related PS1 Mutations. Cell. 2010;141:1146-1158.
Not in our library10.1016/j.cell.2010.05.008
267.
Evans R.J., Wyllie F.S., Wynford-Thomas D., Kipling D., Jones C.J. A P53-dependent, telomere-independent proliferative life span barrier in human astrocytes consistent with the molecular genetics of glioma development. Cancer Res. 2003;63:4854-4861.
Not in our library
268.
Bitto A., Sell C., Crowe E., Lorenzini A., Malaguti M., Hrelia S., Torres C. Stress-induced senescence in human and rodent astrocytes. Exp. Cell Res. 2010;316:2961-2968.
Not in our library10.1016/j.yexcr.2010.06.021
269.
Oddo S.C.A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409-421.
Not in our library10.1016/s0896-6273(03)00434-3
270.
Disruption of oligodendrocyte progenitor cells is an early sign of pathology in the triple transgenic mouse model of Alzheimer's disease · 2020
No notice
271.
Luterman J.D., Haroutunian V., Yemul S., Ho L., Purohit D., Aisen P.S., Mohs R., Pasinetti G.M. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol. 2000;57:1153-1160.
Not in our library10.1001/archneur.57.8.1153
272.
Gruol D.L. IL-6 regulation of synaptic function in the CNS. Neuropharmacology. 2015;96:42-54.
Not in our library10.1016/j.neuropharm.2014.10.023
273.
Iannello A., Thompson T.W., Ardolino M., Lowe S.W., Raulet D.H. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J. Exp. Med. 2013;210:2057-2069.
Not in our library10.1084/jem.20130783
274.
NKG2D ligands mediate immunosurveillance of senescent cells · 2016
No notice
275.
Senescent cells evade immune clearance via HLA-E-mediated NK and CD8+ T cell inhibition · 2019
No notice
276.
Muñoz-Espín D., Cañamero M., Maraver A., Gómez-López G., Contreras J., Murillo-Cuesta S., Rodríguez-Baeza A., Varela-Nieto I., Ruberte J., Collado M., et al. XProgrammed cell senescence during mammalian embryonic development. Cell. 2013;155:1104-1118.
Not in our library10.1016/j.cell.2013.10.019
277.
Kang T.-W., Yevsa T., Woller N., Hoenicke L., Wuestefeld T., Dauch D., Hohmeyer A., Gereke M., Rudalska R., Potapova A., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011;479:547-551.
Not in our library10.1038/nature10599
278.
Krizhanovsky V., Yon M., Dickins R.A., Hearn S., Simon J., Miething C., Yee H., Zender L., Lowe S.W. Senescence of Activated Stellate Cells Limits Liver Fibrosis. Cell. 2008;134:657-667.
Not in our library10.1016/j.cell.2008.06.049
279.
Galea I., Bechmann I., Perry V.H. What is immune privilege (not)? Trends Immunol. 2007;28:12-18.
Not in our library10.1016/j.it.2006.11.004
280.
Korin B., Ben-Shaanan T.L., Schiller M., Dubovik T., Azulay-Debby H., Boshnak N.T., Koren T., Rolls A. High-dimensional, single-cell characterization of the brain’s immune compartment. Nat. Neurosci. 2017;20:1300-1309.
Not in our library10.1038/nn.4610
281.
Benakis C., Llovera G., Liesz A. The meningeal and choroidal infiltration routes for leukocytes in stroke. Ther. Adv. Neurol. Disord. 2018;11:11.
Not in our library10.1177/1756286418783708
282.
Ardura-Fabregat A., Boddeke E.W.G.M., Boza-Serrano A., Brioschi S., Castro-Gomez S., Ceyzériat K., Dansokho C., Dierkes T., Gelders G., Heneka M.T., et al. Targeting Neuroinflammation to Treat Alzheimer’s Disease. CNS Drugs. 2017;31:1057-1082.
Not in our library10.1007/s40263-017-0483-3
283.
Gorlé N., Van Cauwenberghe C., Libert C., Vandenbroucke R.E. The effect of aging on brain barriers and the consequences for Alzheimer’s disease development. Mamm. Genome. 2016;27:407-420.
Not in our library10.1007/s00335-016-9637-8
284.
Sweeney M.D., Sagare A.P., Zlokovic B.V. Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 2018;14:133-150.
Not in our library10.1038/nrneurol.2017.188
285.
Nation D.A., Sweeney M.D., Montagne A., Sagare A.P., D’Orazio L.M., Pachicano M., Sepehrband F., Nelson A.R., Buennagel D.P., Harrington M.G., et al. Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat. Med. 2019;25:270-276.
Not in our library10.1038/s41591-018-0297-y
286.
van de Haar H.J., Burgmans S., Jansen J.F., van Osch M.J., van Buchem M.A., Muller M., Hofman P.A., Verhey F.R., Backes W.H. Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease. Radiology. 2016;281:527-535.
Not in our library10.1148/radiol.2016152244
287.
McManus R.M., Mills K.H., Lynch M.A. T cells—protective or pathogenic in Alzheimer’s disease? J. Neuroimmune Pharmacol. 2015;10:547-560.
Not in our library10.1007/s11481-015-9612-2
288.
Yu J.T., Xu W., Tan C.C., Andrieu S., Suckling J., Evangelou E., Pan A., Zhang C., Jia J., Feng L., et al. Evidence-based prevention of Alzheimer’s disease: Systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J. Neurol. Neurosurg. Psychiatry. 2020;111:1201-1209.
Not in our library10.1136/jnnp-2019-321913
289.
Kivipelto M., Mangialasche F., Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat. Rev. Neurol. 2018;14:653-666.
Not in our library10.1038/s41582-018-0070-3
290.
Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease · 2020
No notice
291.
Kandimalla R., Thirumala V., Reddy P.H. Is Alzheimer’s disease a Type 3 Diabetes? A critical appraisal. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2017;1863:1078-1089.
Not in our library10.1016/j.bbadis.2016.08.018
292.
Sun S., Ji Y., Kersten S., Qi L. Mechanisms of Inflammatory Responses in Obese Adipose Tissue. Annu. Rev. Nutr. 2012;32:261-286.
Not in our library10.1146/annurev-nutr-071811-150623
293.
Mraz M., Haluzik M. The role of adipose tissue immune cells in obesity and low-grade inflammation. J. Endocrinol. 2014;222:R113-R127.
Not in our library10.1530/joe-14-0283
294.
Schenk S., Saberi M., Olefsky J.M. Insulin sensitivity: Modulation by nutrients and inflammation. J. Clin. Investig. 2008;118:2992-3002.
Not in our library10.1172/jci34260
295.
Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease · 2020
No notice
296.
Nguyen T.T., Ta Q.T.H., Nguyen T.T.D., Le T.T., Vo V.G. Role of Insulin Resistance in the Alzheimer’s Disease Progression. Neurochem. Res. 2020;45:1481-1491.
Not in our library10.1007/s11064-020-03031-0
297.
Bahniwal M., Little J.P., Klegeris A. High Glucose Enhances Neurotoxicity and Inflammatory Cytokine Secretion by Stimulated Human Astrocytes. Curr. Alzheimer Res. 2017;14:731-741.
Not in our library10.2174/1567205014666170117104053
298.
Anjum I., Fayyaz M., Wajid A., Sohail W., Ali A. Does Obesity Increase the Risk of Dementia: A Literature Review. Cureus. 2018;10:e2660.
Not in our library10.7759/cureus.2660
299.
Flores-Dorantes M.T., Díaz-López Y.E., Gutiérrez-Aguilar R. Environment and Gene Association With Obesity and Their Impact on Neurodegenerative and Neurodevelopmental Diseases. Front. Neurosci. 2020;28:863.
Not in our library10.3389/fnins.2020.00863
300.
Batatinha H.A., Biondo L.A., Lira F.S., Castell L.M., Rosa-Neto J.C. Nutrients, immune system, and exercise: Where will it take us? Nutrition. 2019;61:151-156.
Not in our library10.1016/j.nut.2018.09.019
301.
Nieman D.C., Lila M.A., Gillitt N.D. Immunometabolism: A Multi-Omics Approach to Interpreting the Influence of Exercise and Diet on the Immune System. Annu. Rev. Food Sci. Technol. 2019;10:341-363.
Not in our library10.1146/annurev-food-032818-121316
302.
Simpson R.J., Lowder T.W., Spielmann G., Bigley A.B., LaVoy E.C., Kunz H. Exercise and the aging immune system. Ageing Res. Rev. 2012;11:404-420.
Not in our library10.1016/j.arr.2012.03.003
303.
Ostrowski K., Rohde T., Zacho M., Asp S., Pedersen B.K. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J. Physiol. 1998;508:949-953.
Not in our library10.1111/j.1469-7793.1998.949bp.x
304.
Ma L., Zhang H., Yin Y.-L., Guo W.-Z., Ma Y.-Q., Wang Y.-B., Shu C., Dong L.-Q. Role of interleukin-6 to differentiate sepsis from non-infectious systemic inflammatory response syndrome. Cytokine. 2016;88:126-135.
Not in our library10.1016/j.cyto.2016.08.033
305.
Febbraio M.A., Hiscock N., Sacchetti M., Fischer C.P., Pedersen B.K. Interleukin-6 Is a Novel Factor Mediating Glucose Homeostasis During Skeletal Muscle Contraction. Diabetes. 2004;53:1643-1648.
Not in our library10.2337/diabetes.53.7.1643
306.
Petersen E.W., Carey A.L., Sacchetti M., Steinberg G.R., Macaulay S.L., Febbraio M.A., Pedersen B.K. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am. J. Physiol. Metab. 2005;288:E155-E162.
Not in our library10.1152/ajpendo.00257.2004
307.
Neto J.C., Silveira L.S. Endurance Exercise Mitigates Immunometabolic Adipose Tissue Disturbances in Cancer and Obesity. Int. J. Mol. Sci. 2020;21:9745.
Not in our library10.3390/ijms21249745
308.
Kwilasz A., Grace P., Serbedzija P., Maier S., Watkins L. The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology. 2015;96:55-69.
Not in our library10.1016/j.neuropharm.2014.10.020
309.
Balancing the immune response in the brain: IL-10 and its regulation · 2016
No notice
310.
Littlefield A.M., Setti S.E., Priester C., Kohman R.A. Voluntary exercise attenuates LPS-induced reductions in neurogenesis and increases microglia expression of a proneurogenic phenotype in aged mice. J. Neuroinflamm. 2015;12:1-12.
Not in our library10.1186/s12974-015-0362-0
311.
Physical Exercise for Individuals with Hypertension: It Is Time to Emphasize its Benefits on the Brain and Cognition · 2019
Not checked
312.
Physical Activity and Brain Health · 2019
No notice
313.
O’Toole P.W., Jeffery I.B. Gut microbiota and aging. Science. 2015;350:1214-1215.
Not in our library10.1126/science.aac8469
314.
Gut Microbial Changes, Interactions, and Their Implications on Human Lifecycle: An Ageing Perspective · 2018
No notice
315.
Diversity, compositional and functional differences between gut microbiota of children and adults · 2020
No notice
316.
Claesson M.J., Jeffery I.B., Conde S., Power S.E., O’Connor E.M., Cusack S., Harris H.M.B., Coakley M., Lakshminarayanan B., O’Sullivan O., et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012;488:178-184.
Not in our library10.1038/nature11319
317.
Jiang C., Li G., Huang P., Liu Z., Zhao B. The Gut Microbiota and Alzheimer’s Disease. J. Alzheimer's Dis. 2017;58:1-15.
Not in our library10.3233/jad-161141
318.
Bostanciklioğlu M. The role of gut microbiota in pathogenesis of Alzheimer’s disease. J. Appl. Microbiol. 2019;127:954-967.
Not in our library10.1111/jam.14264
319.
Systemic Immune Dyshomeostasis Model and Pathways in Alzheimer’s Disease · 2019
Not checked
320.
The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis · 2018
No notice
321.
Muller P.A., Schneeberger M., Matheis F., Wang P., Kerner Z., Ilanges A., Pellegrino K., Del Mármol J., Castro T.B.R., Furuichi M., et al. Microbiota modulate sympathetic neurons via a gut–brain circuit. Nat. Cell Biol. 2020;583:441-446.
Not in our library10.1038/s41586-020-2474-7
322.
Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression · 2019
No notice
323.
Rea K., Dinan T.G., Cryan J.F. The microbiome: A key regulator of stress and neuroinflammation. Neurobiol. Stress. 2016;4:23-33.
Not in our library10.1016/j.ynstr.2016.03.001
324.
Chen J., Buchanan J.B., Sparkman N.L., Godbout J.P., Freund G.G., Johnson R.W. Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system. Brain Behav. Immun. 2008;22:301-311.
Not in our library10.1016/j.bbi.2007.08.014
325.
Role of neuroinflammation in neurodegeneration: new insights · 2017
No notice
326.
Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System · 2019
No notice
327.
Complement in the pathogenesis of Alzheimer’s disease · 2017
Corrected
328.
Tenner A.J., Stevens B., Woodruff T.M. New tricks for an ancient system: Physiological and pathological roles of complement in the CNS. Mol. Immunol. 2018;102:3-13.
Not in our library10.1016/j.molimm.2018.06.264
329.
Wu T., Dejanovic B., Gandham V.D., Gogineni A., Edmonds R., Schauer S., Srinivasan K., Huntley M.A., Wang Y., Wang T.M., et al. Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. Cell Rep. 2019;28:e6-2123.
Not in our library10.1016/j.celrep.2019.07.060
330.
Montagne A., Barnes S.R., Sweeney M.D., Halliday M.R., Sagare A.P., Zhao Z., Toga A.W., Jacobs R.E., Liu C.Y., Amezcua L., et al. Blood-Brain Barrier Breakdown in the Aging Human Hippocampus. Neuron. 2015;85:296-302.
Not in our library10.1016/j.neuron.2014.12.032
331.
Varatharaj A., Galea I. The blood-brain barrier in systemic inflammation. Brain Behav. Immun. 2017;60:1-12.
Not in our library10.1016/j.bbi.2016.03.010
332.
Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy · 2014
No notice
333.
Jaeger L.B., Dohgu S., Sultana R., Lynch J.L., Owen J.B., Erickson M.A., Shah G.N., Price T.O., Fleegal-Demotta M.A., Butterfield D.A., et al. Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: A mechanism for inflammation in the progression of Alzheimer’s disease. Brain Behav. Immun. 2009;23:507-517.
Not in our library10.1016/j.bbi.2009.01.017
334.
Propson N.E., Roy E.R., Litvinchuk A., Köhl J., Zheng H. Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging. J. Clin. Investig. 2021;131:131.
Not in our library10.1172/jci140966
335.
Bhatia K., Ahmad S., Kindelin A., Ducruet A.F. Complement C3a receptor-mediated vascular dysfunction: A complex interplay between aging and neurodegeneration. J. Clin. Investig. 2021;131:e144348.
Not in our library10.1172/jci144348
336.
Liddelow S.A., Guttenplan K.A., Clarke L.E., Bennett F.C., Bohlen C.J., Schirmer L., Bennett M.L., Münch A.E., Chung W.-S., Peterson T.C., et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481-487.
Not in our library10.1038/nature21029
337.
Deciphering the Astrocyte Reaction in Alzheimer’s Disease · 2018
No notice
338.
Seol Y., Ki S., Ryu H.L., Chung S., Lee J., Ryu H. How Microglia Manages Non-cell Autonomous Vicious Cycling of Aβ Toxicity in the Pathogenesis of AD. Front. Mol. Neurosci. 2020;13:13.
Not in our library10.3389/fnmol.2020.593724
339.
Henstridge C.M., Hyman B.T., Spires-Jones T.L. Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis. Nat. Rev. Neurosci. 2019;20:94-108.
Not in our library10.1038/s41583-018-0113-1
340.
Fullerton J.N., Gilroy D.W. Resolution of inflammation: A new therapeutic frontier. Nat. Rev. Drug Discov. 2016;15:551-567.
Not in our library10.1038/nrd.2016.39
341.
Probert L. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience. 2015;302:2-22.
Not in our library10.1016/j.neuroscience.2015.06.038
342.
Choroid plexus tumor necrosis factor receptor 1: A new neuroinflammatory piece of the complex Alzheimer’s disease puzzle · 2019
Not checked
343.
TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation · 2012
No notice
344.
Tumor Necrosis Factor Alpha: A Link between Neuroinflammation and Excitotoxicity · 2014
No notice
345.
Tumor necrosis factor α Inhibition for Alzheimer’s Disease · 2017
Not checked
346.
Paouri E., Tzara O., Kartalou G.-I., Zenelak S., Georgopoulos S. Peripheral Tumor Necrosis Factor-Alpha (TNF-α) Modulates Amyloid Pathology by Regulating Blood-Derived Immune Cells and Glial Response in the Brain of AD/TNF Transgenic Mice. J. Neurosci. 2017;37:5155-5171.
Not in our library10.1523/jneurosci.2484-16.2017
347.
Paouri E., Tzara O., Zenelak S., Georgopoulos S. Genetic Deletion of Tumor Necrosis Factor-α Attenuates Amyloid-β Production and Decreases Amyloid Plaque Formation and Glial Response in the 5XFAD Model of Alzheimer’s Disease. J. Alzheimer’s Dis. 2017;60:165-181.
Not in our library10.3233/jad-170065
348.
Steeland S., Gorlé N., VandenDriessche C., Balusu S., Brkic M., Van Cauwenberghe C., Van Imschoot G., Van Wonterghem E., De Rycke R., Kremer A., et al. Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer’s disease. EMBO Mol. Med. 2018;10:e8300.
Not in our library10.15252/emmm.201708300
349.
Lapadula G., Marchesoni A., Armuzzi A., Blandizzi C., Caporali R., Chimenti S., Cimaz R., Cimino L., Gionchetti P., Girolomoni G., et al. Adalimumab in the Treatment of Immune-Mediated Diseases. Int. J. Immunopathol. Pharmacol. 2014;27:33-48.
Not in our library10.1177/03946320140270s103
350.
Decourt B., Drumm-Gurnee D., Wilson J., Jacobson S., Belden C., Sirrel S., Ahmadi M., Shill H., Powell J., Walker A., et al. Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s disease: Results from a Double-Blind, Placebo-Controlled Trial. Curr. Alzheimer Res. 2017;14:1.
Not in our library10.2174/1567205014666170117141330
351.
Park J., Lee S.-Y., Shon J., Kim K., Lee H.J., Kim K.A., Lee B.-Y., Oh S.-H., Kim N.K., Kim O.J. Adalimumab improves cognitive impairment, exerts neuroprotective effects and attenuates neuroinflammation in an Aβ1-40-injected mouse model of Alzheimer’s disease. Cytotherapy. 2019;21:671-682.
Not in our library10.1016/j.jcyt.2019.04.054
352.
Anwar S., Rivest S. Alzheimer’s disease: Microglia targets and their modulation to promote amyloid phagocytosis and mitigate neuroinflammation. Expert Opin. Ther. Targets. 2020;24:331-344.
Not in our library10.1080/14728222.2020.1738391
353.
Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis · 2020
No notice
354.
Steed P.M., Tansey M.G., Zalevsky J., Zhukovsky E.A., DesJarlais J.R., Szymkowski D.E., Abbott C., Carmichael D., Chan C., Cherry L., et al. Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants. Science. 2003;301:1895-1898.
Not in our library10.1126/science.1081297
355.
Cavanagh C., Tse Y.C., Nguyen H.-B., Krantic S., Breitner J.C., Quirion R., Wong T.P. Inhibiting tumor necrosis factor-α before amyloidosis prevents synaptic deficits in an Alzheimer’s disease model. Neurobiol. Aging. 2016;47:41-49.
Not in our library10.1016/j.neurobiolaging.2016.07.009
356.
MacPherson K.P., Sompol P., Kannarkat G.T., Chang J., Sniffen L., Wildner M.E., Norris C.M., Tansey M.G. Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice. Neurobiol. Dis. 2017;102:81-95.
Not in our library10.1016/j.nbd.2017.02.010
357.
McAlpine F.E., Lee J.K., Harms A.S., Ruhn K.A., Blurton-Jones M., Hong J., Das P., Golde T.E., LaFerla F.M., Oddo S., et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer’s disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol. Dis. 2009;34:163-177.
Not in our library10.1016/j.nbd.2009.01.006
358.
Sama D.M., Mohmmad Abdul H., Furman J.L., Artiushin I.A., Szymkowski D.E., Scheff S.W., Norris C.M. Inhibition of soluble tumor necrosis factor ameliorates synaptic alterations and Ca2+ dysregulation in aged rats. PLoS ONE. 2012;7:e38170.
Not in our library10.1371/journal.pone.0038170
359.
Yiannopoulou K.G., Papageorgiou S.G. Current and Future Treatments in Alzheimer Disease: An Update. J. Cent. Nerv. Syst. Dis. 2020;12:1179573520907397.
Not in our library10.1177/1179573520907397
360.
Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments · 2019
No notice
361.
Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease. · 2013
Not checked
362.
Decourt B., Wilson J., Ritter A., Dardis C., DiFilippo F.P., Zhuang X., Cordes D., Lee G., Fulkerson N.D., Rose T.S., et al. MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease. Open Access J. Clin. Trials. 2020;ume 12:1-13.
Not in our library10.2147/oajct.s221914
363.
Tumor necrosis factor-α synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease · 2012
No notice
364.
Lin C.T., Lecca D., Yang L.Y., Luo W., Scerba M.T., Tweedie D., Huang P.S., Jung Y.J., Kim D.S., Yang C.H., et al. 3,6’-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation. Elife. 2020;9:e54726.
Not in our library10.7554/elife.54726
365.
Russo I., Caracciolo L., Tweedie D., Choi S.-H., Greig N.H., Barlati S., Bosetti F. 3,6′-Dithiothalidomide, a new TNF-α synthesis inhibitor, attenuates the effect of Aβ1-42 intracerebroventricular injection on hippocampal neurogenesis and memory deficit. J. Neurochem. 2012;122:1181-1192.
Not in our library10.1111/j.1471-4159.2012.07846.x
366.
Gabbita S.P., Srivastava M.K., Eslami P., Johnson M.F., Kobritz N.K., Tweedie D., Greig N.H., Zemlan F.P., Sharma S.P., Harris-White M.E. Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer’s disease. J. Neuroinflamm. 2012;9:236.
Not in our library10.1186/1742-2094-9-99
367.
Kirkland J.L., Tchkonia T., Zhu Y., Niedernhofer L.J., Robbins P.D. The Clinical Potential of Senolytic Drugs. J. Am. Geriatr. Soc. 2017;65:2297-2301.
Not in our library10.1111/jgs.14969
368.
Cellular Senescence: A Translational Perspective · 2017
Not checked
369.
New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463 · 2017
No notice
370.
Baker D.J., Petersen R.C. Cellular senescence in brain aging and neurodegenerative diseases: Evidence and perspectives. J. Clin. Investig. 2018;128:1208-1216.
Not in our library10.1172/jci95145
371.
Farr J.N., Fraser D.G., Wang H., Jaehn K., Ogrodnik M.B., Weivoda M.M., Drake M.T., Tchkonia T., Lebrasseur N.K., Kirkland J.L., et al. Identification of Senescent Cells in the Bone Microenvironment. J. Bone Miner. Res. 2016;31:1920-1929.
Not in our library10.1002/jbmr.2892
372.
Chronic inflammation induces telomere dysfunction and accelerates ageing in mice · 2014
No notice
373.
Sabogal-Guaqueta A.M., Munoz-Manco J.I., Ramirez-Pineda J.R., Lamprea-Rodriguez M., Osorio E., Cardona-Gomez G.P. The flavonoid quercetin ameliorates Alzheimer’s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer’s disease model mice. Neuropharmacology. 2015;93:134-145.
Not in our library10.1016/j.neuropharm.2015.01.027
374.
Kirkland J.L., Tchkonia T. Senolytic drugs: From discovery to translation. J. Intern. Med. 2020;288:518-536.
Not in our library10.1111/joim.13141
375.
Wissler Gerdes E.O., Zhu Y., Weigand B.M., Tripathi U., Burns T.C., Tchkonia T., Kirkland J.L. Cellular senescence in aging and age-related diseases: Implications for neurodegenerative diseases. Int. Rev. Neurobiol. 2020;155:203-234.
Not in our library10.1016/bs.irn.2020.03.019
376.
Yousefzadeh M.J., Zhu Y., McGowan S.J., Angelini L., Fuhrmann-Stroissnigg H., Xu M., Ling Y.Y., Melos K.I., Pirtskhalava T., Inman C.L., et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28.
Not in our library10.1016/j.ebiom.2018.09.015
377.
Garbarino V.R., Tran S., E Glassman J., Kirkland J.L., Musi N., Seshadri S., E Orr M. A head-to-head comparison between senolytic therapies, dasatinib plus quercetin and fisetin, indicates sex- and genotype-specific differences in translationally relevant outcomes. Alzheimer’s Dement. 2020;16.
Not in our library10.1002/alz.047607
378.
Jiang H., Gong T., Zhou R. The strategies of targeting the NLRP3 inflammasome to treat inflammatory diseases. Adv. Immunol. 2020;145:55-93.
Not in our library10.1016/bs.ai.2019.11.003
379.
Therapeutic modulation of inflammasome pathways · 2020
No notice
380.
Inflammasome activation and regulation: toward a better understanding of complex mechanisms · 2020
No notice
381.
Goldberg E.L., Dixit V.D. Drivers of age-related inflammation and strategies for healthspan extension. Immunol Rev. 2015;265:63-74.
Not in our library10.1111/imr.12295
382.
El-Sharkawy L.Y., Brough D., Freeman S. Inhibiting the NLRP3 Inflammasome. Molecules. 2020;25:5533.
Not in our library10.3390/molecules25235533
383.
Coll R.C., Robertson A.A.B., Chae J.J., Higgins S.C., Muñoz-Planillo R., Inserra M.C., Vetter I., Dungan L.S., Monks B.G., Stutz A., et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 2015;21:248-255.
Not in our library10.1038/nm.3806
384.
Coll R.C., Hill J.R., Day C.J., Zamoshnikova A., Boucher D., Massey N.L., Chitty J.L., Fraser J.A., Jennings M.P., Robertson A.A.B., et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat. Chem. Biol. 2019;15:556-559.
Not in our library10.1038/s41589-019-0277-7
385.
Jiang M., Li R., Lyu J., Li X., Wang W., Wang Z., Sheng H., Zhang W., Karhausen J., Yang W. MCC950, a selective NLPR3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation. J. Neuroinflamm. 2020;17:256.
Not in our library10.1186/s12974-020-01933-y
386.
Dempsey C., Rubio Araiz A., Bryson K.J., Finucane O., Larkin C., Mills E.L., Robertson A.A., Cooper M.A., O’Neill L.A., Lynch M.A. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain Behav. Immun. 2017;61:306-316.
Not in our library10.1016/j.bbi.2016.12.014
387.
Riella L.V., Paterson A.M., Sharpe A.H., Chandraker A. Role of the PD-1 Pathway in the Immune Response. Arab. Archaeol. Epigr. 2012;12:2575-2587.
Not in our library10.1111/j.1600-6143.2012.04224.x
388.
Zhao J., Ji R.-R. Anti-PD-1 treatment as a neurotherapy to enhance neuronal excitability, synaptic plasticity and memory. bioRxiv. 2019;2019.
Not in our library10.1101/870600
389.
Laumet G., Ma J., Robison A.J., Kumari S., Heijnen C.J., Kavelaars A. T Cells as an Emerging Target for Chronic Pain Therapy. Front. Mol. Neurosci. 2019;12:216.
Not in our library10.3389/fnmol.2019.00216
390.
Chamoto K., Al-Habsi M., Honjo T. Role of PD-1 in Immunity and Diseases. Curr. Top. Microbiol. Immunol. 2017;410:75-97.
Not in our library10.1007/82_2017_67
391.
Curdy N., Lanvin O., Laurent C., Fournié J.-J., Franchini D.-M. Regulatory Mechanisms of Inhibitory Immune Checkpoint Receptors Expression. Trends Cell Biol. 2019;29:777-790.
Not in our library10.1016/j.tcb.2019.07.002
392.
Breaking immune tolerance by targeting Foxp3+ regulatory T cells mitigates Alzheimer’s disease pathology · 2015
No notice
393.
Santarpia M., González-Cao M., Viteri S., Karachaliou N., Altavilla G., Rosell R. Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: Understanding transforming growth factor-beta role. Transl. Lung Cancer Res. 2015;4:728-742.
Not in our library10.3978/j.issn.2218-6751.2015.12.04
394.
Schwartz M., Arad M., Ben-Yehuda H. Potential immunotherapy for Alzheimer disease and age-related dementia. Dialog. Clin. Neurosci. 2019;21:21-25.
Not in our library10.31887/dcns.2019.21.1/mschwartz
395.
Munafò A., Burgaletto C., Di Benedetto G., Di Mauro M., Di Mauro R., Bernardini R., Cantarella G. Repositioning of Immunomodulators: A Ray of Hope for Alzheimer’s Disease? Front. Neurosci. 2020;14:14.
Not in our library10.3389/fnins.2020.614643
396.
Baruch K., Deczkowska A., Rosenzweig N., Tsitsou-Kampeli A., Sharif A.M., Matcovitch-Natan O., Kertser A., David E., Amit I., Schwartz M. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease. Nat. Med. 2016;22:135-137.
Not in our library10.1038/nm.4022
397.
Rogers N.K., Romero C., Sanmartín C.D., Ponce D.P., Salech F., López M.N., Gleisner A., Tempio F., Behrens M.I. Inverse Relationship Between Alzheimer’s Disease and Cancer: How Immune Checkpoints Might Explain the Mechanisms Underlying Age-Related Diseases. J. Alzheimer’s Dis. 2020;73:443-454.
Not in our library10.3233/jad-190839
398.
PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model · 2019
No notice
399.
Latta-Mahieu M., Elmer B., Bretteville A., Wang Y., Lopez-Grancha M., Goniot P., Moindrot N., Ferrari P., Blanc V., Schussler N., et al. Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models. Glia. 2017;66:492-504.
Not in our library10.1002/glia.23260
400.
Obst J., Mancuso R., Simon E., Gomez-Nicola D. PD-1 deficiency is not sufficient to induce myeloid mobilization to the brain or alter the inflammatory profile during chronic neurodegeneration. Brain Behav. Immun. 2018;73:708-716.
Not in our library10.1016/j.bbi.2018.08.006
401.
Li S., Hayden E.Y., Garcia V.J., Fuchs D.-T., Sheyn J., Daley D.A., Rentsendorj A., Torbati T., Black K.L., Rutishauser U., et al. Activated bone marrow-derived macrophages eradicate Alzheimer’s-related Aβ42 Oligomers and protect synapses. Front. Immunol. 2020;11:49.
Not in our library10.3389/fimmu.2020.00049
402.
van de Donk N.W.C.J. Immunomodulatory effects of CD38-targeting antibodies. Immunol. Lett. 2018;199:16-22.
Not in our library10.1016/j.imlet.2018.04.005
403.
CD38 in Neurodegeneration and Neuroinflammation · 2020
No notice
404.
Blacher E., Dadali T., Bespalko A., Msc V.J.H., Grimm M.O.W., Hartmann T., Lund F.E., Stein R., Levy A. Alzheimer’s disease pathology is attenuated in a CD38-deficient mouse model. Ann. Neurol. 2015;78:88-103.
Not in our library10.1002/ana.24425
405.
Zhao L. CD33 in Alzheimer’s Disease—Biology, Pathogenesis, and Therapeutics: A Mini-Review. Gerontology. 2019;65:323-331.
Not in our library10.1159/000492596
406.
Malik M., Simpson J.F., Parikh I., Wilfred B.R., Fardo D.W., Nelson P.T., Estus S. CD33 Alzheimer’s Risk-Altering Polymorphism, CD33 Expression, and Exon 2 Splicing. J. Neurosci. 2013;33:13320-13325.
Not in our library10.1523/jneurosci.1224-13.2013
407.
Griciuc A., Serrano-Pozo A., Parrado A.R., Lesinski A.N., Asselin C.N., Mullin K., Hooli B., Choi S.H., Hyman B.T., Tanzi R.E. Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta. Neuron. 2013;78:631-643.
Not in our library10.1016/j.neuron.2013.04.014
408.
Miles L.A., Hermans S.J., Crespi G.A., Gooi J.H., Doughty L., Nero T.L., Markulić J., Ebneth A., Wroblowski B., Oehlrich D., et al. Small Molecule Binding to Alzheimer Risk Factor CD33 Promotes Aβ Phagocytosis. iScience. 2019;19:110-118.
Not in our library10.1016/j.isci.2019.07.023
409.
Vom Berg J., Prokop S., Miller K.R., Obst J., Kälin R.E., Lopategui-Cabezas I., Wegner A., Mair F., Schipke C.G., Peters O., et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s disease-like pathology and cognitive decline. Nat. Med. 2012;18:1812-1819.
Not in our library10.1038/nm.2965
410.
Town T., Vendrame M., Patel A., Poetter D., DelleDonne A., Mori T., Smeed R., Crawford F., Klein T., Tan J., et al. Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer’s beta-amyloid(1-42). J. Neuroimmunol. 2002;132:49-59.
Not in our library10.1016/s0165-5728(02)00307-7
411.
Hu W.T., Holtzman D.M., Fagan A.M., Shaw L.M., Perrin R., Arnold S.E., Grossman M., Xiong C., Craig-Schapiro R., Clark C.M., et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology. 2012;79:897-905.
Not in our library10.1212/wnl.0b013e318266fa70
412.
Teng M.W.L., Bowman E.P., McElwee J.J., Smyth M.J., Casanova J.-L., Cooper A.M., Cua D.J. IL-12 and IL-23 cytokines: From discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 2015;21:719-729.
Not in our library10.1038/nm.3895
413.
Scott L.J. Glatiramer acetate: A review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. CNS Drugs. 2013;27:971-988.
Not in our library10.1007/s40263-013-0117-3
414.
Arnon R., Aharoni R. Glatiramer Acetate: From Bench to Bed and Back. ISR Med. Assoc. J. 2019;21:151-157.
Not in our library
415.
Chen L., Yao Y., Wei C., Sun Y., Ma X., Zhang R., Xu X., Hao J. T cell immunity to glatiramer acetate ameliorates cognitive deficits induced by chronic cerebral hypoperfusion by modulating the microenvironment. Sci. Rep. 2015;5:14308.
Not in our library10.1038/srep14308
416.
Vieira P.L., Heystek H.C., Wormmeester J., Wierenga E.A., Kapsenberg M.L. Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells. J. Immunol. 2003;170:4483-4488.
Not in our library10.4049/jimmunol.170.9.4483
417.
Lalive P.H., Neuhaus O., Benkhoucha M., Burger D., Hohlfeld R., Zamvil S.S., Weber M.S. Glatiramer acetate in the treatment of multiple sclerosis: Emerging concepts regarding its mechanism of action. CNS Drugs. 2011;25:401-414.
Not in our library10.2165/11588120-000000000-00000
418.
Koronyo Y., Salumbides B.C., Sheyn J., Pelissier L., Li S., Ljubimov V., Moyseyev M., Daley D., Fuchs D.-T., Pham M., et al. Therapeutic effects of glatiramer acetate and grafted CD115+monocytes in a mouse model of Alzheimer’s disease. Brain. 2015;138:2399-2422.
Not in our library10.1093/brain/awv150
419.
Butovsky O., Koronyo-Hamaoui M., Kunis G., Ophir E., Landa G., Cohen H., Schwartz M. Glatiramer acetate fights against Alzheimer’s disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc. Natl. Acad. Sci. USA. 2006;103:11784-11789.
Not in our library10.1073/pnas.0604681103
420.
Frenkel D., Maron R., Burt D.S., Weiner H.L. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J. Clin. Investig. 2005;115:2423-2433.
Not in our library10.1172/jci23241
421.
Bakalash S., Pham M., Koronyo Y., Salumbides B.C., Kramerov A., Seidenberg H., Berel D., Black K.L., Koronyo-Hamaoui M. Egr1 Expression Is Induced Following Glatiramer Acetate Immunotherapy in Rodent Models of Glaucoma and Alzheimer’s Disease. Investig. Opthalmology Vis. Sci. 2011;52:9033-9046.
Not in our library10.1167/iovs.11-7498
422.
Khanna A.K. MECHANISM OF THE COMBINATION IMMUNOSUPPRESSIVE EFFECTS OF RAPAMYCIN WITH EITHER CYCLOSPORINE OR TACROLIMUS. Transplantation. 2000;70:690-694.
Not in our library10.1097/00007890-200008270-00027
423.
Lee R.K.K., Knapp S., Wurtman R.J. Prostaglandin E2 Stimulates Amyloid Precursor Protein Gene Expression: Inhibition by Immunosuppressants. J. Neurosci. 1999;19:940-947.
Not in our library10.1523/jneurosci.19-03-00940.1999
424.
Rojanathammanee L., Floden A.M., Manocha G.D., Combs C.K. Attenuation of microglial activation in a mouse model of Alzheimer’s disease via NFAT inhibition. J. Neuroinflamm. 2015;12:42.
Not in our library10.1186/s12974-015-0255-2
425.
Rozkalne A., Hyman B.T., Spires-Jones T.L. Calcineurin inhibition with FK506 ameliorates dendritic spine density deficits in plaque-bearing Alzheimer model mice. Neurobiol. Dis. 2011;41:650-654.
Not in our library10.1016/j.nbd.2010.11.014
426.
Kumar A., Singh N. Calcineurin inhibitors improve memory loss and neuropathological changes in mouse model of dementia. Pharmacol. Biochem. Behav. 2017;153:147-159.
Not in our library10.1016/j.pbb.2016.12.018
427.
Alam J., Blackburn K., Patrick D. Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer’s Disease. J. Prev. Alzheimer's Dis. 2017;4:273-278.
Not in our library10.14283/jpad.2017.41
428.
Alam J.J. Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats. J. Alzheimer’s Dis. 2015;48:219-227.
Not in our library10.3233/jad-150277
429.
Fonseca M.I., Ager R.R., Chu S.-H., Yazan O., Sanderson S.D., LaFerla F.M., Taylor S.M., Woodruff T.M., Tenner A.J. Treatment with a C5aR Antagonist Decreases Pathology and Enhances Behavioral Performance in Murine Models of Alzheimer’s Disease. J. Immunol. 2009;183:1375-1383.
Not in our library10.4049/jimmunol.0901005
430.
Hong S., Beja-Glasser V.F., Nfonoyim B.M., Frouin A., Li S., Ramakrishnan S., Merry K.M., Shi Q., Rosenthal A., Barres B.A., et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712-716.
Not in our library10.1126/science.aad8373
431.
Lansita J.A., Mease K.M., Qiu H., Yednock T., Sankaranarayanan S., Kramer S. Nonclinical Development of ANX005: A Humanized Anti-C1q Antibody for Treatment of Autoimmune and Neurodegenerative Diseases. Int. J. Toxicol. 2017;36:449-462.
Not in our library10.1177/1091581817740873
432.
Mathieu M.-C., Sawyer N., Greig G.M., Hamel M., Kargman S., Ducharme Y., Lau C.K., Friesen R.W., O’Neill G.P., Gervais F.G., et al. The C3a receptor antagonist SB 290157 has agonist activity. Immunol. Lett. 2005;100:139-145.
Not in our library10.1016/j.imlet.2005.03.003
433.
Porrini V., Lanzillotta A., Branca C., Benarese M., Parrella E., Lorenzini L., Calza L., Flaibani R., Spano P., Imbimbo B., et al. CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid. Neuroscience. 2015;302:112-120.
Not in our library10.1016/j.neuroscience.2014.10.029
434.
Mechanisms of Lifespan Regulation by Calorie Restriction and Intermittent Fasting in Model Organisms · 2020
No notice
435.
Dorling J.L., Martin C.K., Redman L.M. Calorie restriction for enhanced longevity: The role of novel dietary strategies in the present obesogenic environment. Ageing Res. Rev. 2020;64:101038.
Not in our library10.1016/j.arr.2020.101038
436.
Chung H.Y., Kim H.J., Kim J.W., Yu B.P. The inflammation hypothesis of aging: Molecular modulation by calorie restriction. Ann. N. Y. Acad. Sci. 2001;928:327-335.
Not in our library10.1111/j.1749-6632.2001.tb05662.x
437.
Di Francesco A., Di Germanio C., Bernier M., de Cabo R. A time to fast. Science. 2018;362:770-775.
Not in our library10.1126/science.aau2095
438.
Wang Y.-W., He S.-J., Feng X., Cheng J., Luo Y.-T., Tian L., Huang Q. Metformin: A review of its potential indications. Drug Des. Dev. Ther. 2017;ume 11:2421-2429.
Not in our library10.2147/dddt.s141675
439.
Vieira R., Souto S.B., Sánchez-López E., Machado A.L., Severino P., Jose S., Santini A., Fortuna A., García M.L., Silva A.M. Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I. Pharmaceuticals. 2019;12:152.
Not in our library10.3390/ph12040152
440.
Partridge L., Piper M.D., Mair W. Dietary restriction in Drosophila. Mech. Ageing Dev. 2005;126:938-950.
Not in our library10.1016/j.mad.2005.03.023
441.
Masoro E.J. Caloric restriction and aging: An update. Exp. Gerontol. 2000;35:299-305.
Not in our library10.1016/s0531-5565(00)00084-x
442.
Metformin Induces a Dietary Restriction–Like State and the Oxidative Stress Response to Extend C. elegans Healthspan via AMPK, LKB1, and SKN-1 · 2010
No notice
443.
Bharath L.P., Agrawal M., McCambridge G., Nicholas D.A., Hasturk H., Liu J., Jiang K., Liu R., Guo Z., Deeney J., et al. Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated Inflammation. Cell Metab. 2020;32:44-55.e6.
Not in our library10.1016/j.cmet.2020.04.015
444.
Kang E.B., Koo J.H., Jang Y.C., Yang C.H., Lee Y., Cosio-Lima L.M., Cho J.Y. Neuroprotective Effects of Endurance Exercise Against High-Fat Diet-Induced Hippocampal Neuroinflammation. J. Neuroendocrinol. 2016;28.
Not in our library10.1111/jne.12385
445.
Park J., Cheon W., Kim K. Effects of Long-Term Endurance Exercise and Lithium Treatment on Neuroprotective Factors in Hippocampus of Obese Rats. Int. J. Environ. Res. Public Heal. 2020;17:3317.
Not in our library10.3390/ijerph17093317
446.
Onyango I.G., Lu J., Rodova M., Lezi E., Crafter A.B., Swerdlow R.H. Regulation of neuron mitochondrial biogenesis and relevance to brain health. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2010;1802:228-234.
Not in our library10.1016/j.bbadis.2009.07.014
447.
Radak Z., Suzuki K., Higuchi M., Balogh L., Boldogh I., Koltai E. Physical exercise, reactive oxygen species and neuroprotection. Free Radic. Biol. Med. 2016;98:187-196.
Not in our library10.1016/j.freeradbiomed.2016.01.024
448.
Intlekofer K.A., Cotman C.W. Exercise counteracts declining hippocampal function in aging and Alzheimer’s disease. Neurobiol. Dis. 2013;57:47-55.
Not in our library10.1016/j.nbd.2012.06.011
449.
The Role of Inflammation in Age-Related Sarcopenia · 2017
No notice
450.
Nilsson M.I., Bourgeois J.M., Nederveen J.P., Leite M.R., Hettinga B.P., Bujak A.L., May L., Lin E., Crozier M., Rusiecki D.R., et al. Lifelong aerobic exercise protects against inflammaging and cancer. PLoS ONE. 2019;14:e0210863.
Not in our library10.1371/journal.pone.0210863
451.
Hardeland R. Melatonin and inflammation-Story of a double-edged blade. J. Pineal Res. 2018;65:e12525.
Not in our library10.1111/jpi.12525
452.
Aging, Melatonin, and the Pro- and Anti-Inflammatory Networks · 2019
No notice
453.
Marchal J., Pifferi F., Aujard F. Resveratrol in mammals: Effects on aging biomarkers, age-related diseases, and life span. Ann. N. Y. Acad. Sci. 2013;1290:67-73.
Not in our library10.1111/nyas.12214
454.
Alcaín F.J., Villalba J.M. Sirtuin activators. Expert. Opin. Ther. Pat. 2009;19:403-414.
Not in our library10.1517/13543770902762893
455.
Activation of Sirt1 by Resveratrol Inhibits TNF-α Induced Inflammation in Fibroblasts · 2011
No notice
456.
Resveratrol Derivatives as Potential Treatments for Alzheimer’s and Parkinson’s Disease · 2020
No notice
457.
Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease · 2017
No notice
458.
Turner R.S., Thomas R.G., Craft S., Van Dyck C.H., Mintzer J., Reynolds B.A., Brewer J.B., Rissman R.A., Raman R., Aisen P.S., et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85:1383-1391.
Not in our library10.1212/wnl.0000000000002035
459.
Witte A.V., Kerti L., Margulies D.S., Flöel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J. Neurosci. 2014;34:7862-7870.
Not in our library10.1523/jneurosci.0385-14.2014
460.
The Beneficial Roles of SIRT1 in Neuroinflammation-Related Diseases · 2020
No notice
461.
Cannizzo E.S., Clement C.C., Sahu R., Follo C., Santambrogio L. Oxidative stress, inflamm-aging and immunosenescence. J. Proteom. 2011;74:2313-2323.
Not in our library10.1016/j.jprot.2011.06.005
462.
Bachmann M.C., Bellalta S., Basoalto R., Gómez-Valenzuela F., Jalil Y., Lépez M., Matamoros A., Von Bernhardi R. The Challenge by Multiple Environmental and Biological Factors Induce Inflammation in Aging: Their Role in the Promotion of Chronic Disease. Front. Immunol. 2020;11:570083.
Not in our library10.3389/fimmu.2020.570083
463.
Chelombitko M.A. Role of Reactive Oxygen Species in Inflammation: A Minireview. Mosc. Univ. Biol. Sci. Bull. 2018;73:199-202.
Not in our library10.3103/s009639251804003x
464.
Mitochondria-Targeted Antioxidants: A Step towards Disease Treatment · 2020
No notice
465.
Fujimoto C., Yamasoba T. Mitochondria-Targeted Antioxidants for Treatment of Hearing Loss: A Systematic Review. Antioxidants. 2019;8:109.
Not in our library10.3390/antiox8040109
466.
Oyewole A.O., Birch-Machin M.A. Mitochondria-targeted antioxidants. FASEB J. 2015;29:4766-4771.
Not in our library10.1096/fj.15-275404
467.
Fang Y., Hu X.H., Jia Z.G., Xu M.H., Guo Z.Y., Gao F.H. Tiron protects against UVB-induced senescence-like characteristics in human dermal fibroblasts by the inhibition of superoxide anion production and glutathione depletion. Australas. J. Dermatol. 2012;53:172-180.
Not in our library10.1111/j.1440-0960.2012.00912.x
468.
For The Carmis Study Group, Piermarocchi S., Saviano S., Parisi V., Tedeschi M., Panozzo G., Scarpa G., Boschi G., Giudice G.L., Sartore M., et al. Carotenoids in Age-Related Maculopathy Italian Study (CARMIS): Two-Year Results of a Randomized Study. Eur. J. Ophthalmol. 2012;22:216-225.
Not in our library10.5301/ejo.5000069
469.
Wu W., Wang X., Xiang Q., Meng X., Peng Y., Du N., Liu Z., Sun Q., Wang C., Liu X. Astaxanthin alleviates brain aging in rats by attenuating oxidative stress and increasing BDNF levels. Food Funct. 2013;5:158-166.
Not in our library10.1039/c3fo60400d
470.
Gill H.S., Rutherfurd K.J., Cross M.L., Gopal P.K. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am. J. Clin. Nutr. 2001;74:833-839.
Not in our library10.1093/ajcn/74.6.833
471.
Dong H., Rowland I., Thomas L.V., Yaqoob P. Immunomodulatory effects of a probiotic drink containing Lactobacillus casei Shirota in healthy older volunteers. Eur. J. Nutr. 2013;52:1853-1863.
Not in our library10.1007/s00394-012-0487-1
472.
Vulevic J., Drakoularakou A., Yaqoob P., Tzortzis G., Gibson G.R. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. Am. J. Clin. Nutr. 2008;88:1438-1446.
Not in our library10.3945/ajcn.2008.26242
473.
Frasca D., Blomberg B.B. Inflammaging decreases adaptive and innate immune responses in mice and humans. Biogerontology. 2016;17:7-19.
Not in our library10.1007/s10522-015-9578-8
474.
Man A.W.C., Zhou Y., Xia N., Li H. Involvement of Gut Microbiota, Microbial Metabolites and Interaction with Polyphenol in Host Immunometabolism. Nutrients. 2020;12:3054.
Not in our library10.3390/nu12103054
475.
Antibiotics, gut microbiota, and Alzheimer’s disease · 2019
No notice
476.
He Y., Li B., Sun D., Chen S. Gut Microbiota: Implications in Alzheimer’s Disease. J. Clin. Med. 2020;9:2042.
Not in our library10.3390/jcm9072042
477.
Alzheimer’s Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway · 2019
No notice
478.
Zhu F., Li C., Chu F., Tian X., Zhu J. Target Dysbiosis of Gut Microbes as a Future Therapeutic Manipulation in Alzheimer’s Disease. Front. Aging Neurosci. 2020;12:544235.
Not in our library10.3389/fnagi.2020.544235
479.
Sharma R., Padwad Y. Probiotic bacteria as modulators of cellular senescence: Emerging concepts and opportunities. Gut Microbes. 2020;11:335-349.
Not in our library10.1080/19490976.2019.1697148
480.
Crosstalk between Gut and Brain in Alzheimer’s Disease: The Role of Gut Microbiota Modulation Strategies · 2021
No notice
481.
Kesika P., Suganthy N., Sivamaruthi B.S., Chaiyasut C. Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer’s disease. Life Sci. 2021;264:118627.
Not in our library10.1016/j.lfs.2020.118627
482.
Bonfili L., Cecarini V., Gogoi O., Gong C., Cuccioloni M., Angeletti M., Rossi G., Eleuteri A.M. Microbiota modulation as preventative and therapeutic approach in Alzheimer’s disease. FEBS J. 2020.
Not in our library10.1111/febs.15571
483.
Gut Microbiota and Dysbiosis in Alzheimer’s Disease: Implications for Pathogenesis and Treatment · 2020
No notice
484.
Portis S.M., Chaput D., Burroughs B., Hudson C., Sanberg P.R., Bickford P.C. Effects of nutraceutical intervention on serum proteins in aged rats. GeroScience. 2020;42:703-713.
Not in our library10.1007/s11357-020-00174-4
485.
Sadhukhan P., Saha S., Dutta S., Mahalanobish S., Sil P.C. Nutraceuticals: An emerging therapeutic approach against the pathogenesis of Alzheimer’s disease. Pharmacol. Res. 2018;129:100-114.
Not in our library10.1016/j.phrs.2017.11.028
486.
Calfio C., Gonzalez A., Singh S.K., Rojo L.E., Maccioni R.B. The Emerging Role of Nutraceuticals and Phytochemicals in the Prevention and Treatment of Alzheimer’s Disease. J. Alzheimer’s Dis. 2020;77:33-51.
Not in our library10.3233/jad-200443
487.
Vaiserman A., Koliada A., Lushchak O. Neuroinflammation in pathogenesis of Alzheimer’s disease: Phytochemicals as potential therapeutics. Mech. Ageing Dev. 2020;189:111259.
Not in our library10.1016/j.mad.2020.111259
488.
Flowers A., Lee J.-Y., Acosta S., Hudson C., Small B., Sanberg C.D., Bickford P.C., Grimmig B. NT-020 treatment reduces inflammation and augments Nrf-2 and Wnt signaling in aged rats. J. Neuroinflamm. 2015;12:174.
Not in our library10.1186/s12974-015-0395-4
489.
Alpert P.T. The Role of Vitamins and Minerals on the Immune System. Home Heal. Care Manag. Pr. 2017;29:199-202.
Not in our library10.1177/1084822317713300
490.
Mora J.R., Iwata M., von Andrian U.H. Vitamin effects on the immune system: Vitamins A and D take centre stage. Nat. Rev. Immunol. 2008;8:685-698.
Not in our library10.1038/nri2378
491.
Immune Function and Micronutrient Requirements Change over the Life Course · 2018
No notice
492.
Abiri B., Vafa M. Micronutrients that Affect Immunosenescence. Adv. Exp. Med. Biol. 2020;1260:13-31.
Not in our library10.1007/978-3-030-42667-5_2
493.
Meydani S.N., Meydani M., Blumberg J.B., Leka L.S., Siber G., Loszewski R., Thompson C., Pedrosa M.C., Diamond R.D., Stollar B.D. Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. JAMA. 1997;277:1380-1386.
Not in our library10.1001/jama.1997.03540410058031
494.
De la Fuente M., Hernanz A., Guayerbas N., Victor V.M., Arnalich F. Vitamin E ingestion improves several immune functions in elderly men and women. Free Radic Res. 2008;42:272-280.
Not in our library10.1080/10715760801898838
495.
Pallast E.G., Schouten E.G., De Waart F.G., Fonk H.C., Doekes G., Von Blomberg B.M., Kok F.J. Effect of 50- and 100-mg vitamin E supplements on cellular immune function in noninstitutionalized elderly persons. Am. J. Clin. Nutr. 1999;69:1273-1281.
Not in our library10.1093/ajcn/69.6.1273
496.
Antioxidant and Oxidative Stress: A Mutual Interplay in Age-Related Diseases · 2018
No notice
497.
Tan B.L., Norhaizan M.E. Carotenoids: How Effective Are They to Prevent Age-Related Diseases? Molecules. 2019;24:1801.
Not in our library10.3390/molecules24091801
498.
Vitamin C, Aging and Alzheimer’s Disease · 2017
No notice
499.
Maggini S., Wintergerst E.S., Beveridge S., Hornig D.H. Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses. Br. J. Nutr. 2007;98:S29-S35.
Not in our library10.1017/s0007114507832971
500.
Zhitkovich A. Nuclear and Cytoplasmic Functions of Vitamin C. Chem. Res. Toxicol. 2020;33:2515-2526.
Not in our library10.1021/acs.chemrestox.0c00348
501.
Vitamin C and Infections · 2017
No notice
502.
Vitamin C and Immune Function · 2017
No notice
503.
Tanaka M., Muto N., Gohda E., Yamamoto I. Enhancement by Ascorbic Acid 2-Glucoside or Repeated Additions of Ascorbate of Mitogen-Induced IgM and IgG Productions by Human Peripheral Blood Lymphocytes. Jpn. J. Pharmacol. 1994;66:451-456.
Not in our library10.1254/jjp.66.451
504.
Cabrera Á.J.R. Zinc, aging, and immunosenescence: An overview. Pathobiol. Aging Age-Related Dis. 2015;5:25592.
Not in our library10.3402/pba.v5.25592
505.
Antioxidant and anti-inflammatory effects of zinc. Zinc-dependent NF-κB signaling · 2017
No notice
506.
Wong C.P., Ho E. Zinc and its role in age-related inflammation and immune dysfunction. Mol. Nutr. Food Res. 2012;56:77-87.
Not in our library10.1002/mnfr.201100511
507.
Prasad A.S. Clinical, immunological, anti-inflammatory and antioxidant roles of zinc. Exp. Gerontol. 2008;43:370-377.
Not in our library10.1016/j.exger.2007.10.013
508.
Fortes C., Forastiere F., Agabiti N., Fano V., Pacifici R., Virgili F., Piras G., Guidi L., Bartoloni C., Tricerri A., et al. The Effect of Zinc and Vitamin A Supplementation on Immune Response in an Older Population. J. Am. Geriatr. Soc. 1998;46:19-26.
Not in our library10.1111/j.1532-5415.1998.tb01008.x
509.
Critical Role of Zinc as Either an Antioxidant or a Prooxidant in Cellular Systems · 2018
No notice
510.
The Role of Micronutrients in Support of the Immune Response against Viral Infections · 2020
No notice
511.
Prasad A.S., Bao B., Beck F.W., Kucuk O., Sarkar F.H. Antioxidant effect of zinc in humans. Free. Radic. Biol. Med. 2004;37:1182-1190.
Not in our library10.1016/j.freeradbiomed.2004.07.007
512.
Xia S., Shen Y., Yu W. Study on mechanism and intervention of inflamm-aging in rats. Chin. J. Gerontol. 2009;29:2595-2598.
Not in our library
513.
Xia S., Shen Y., Yu W. Inflamm-aging related genes expression in aged rat hippocampus and Icariin intervention outcome. Geriatr. Health Care. 2008;14:340-344.
Not in our library
514.
Icariin improves brain function decline in aging rats by enhancing neuronal autophagy through the AMPK/mTOR/ULK1 pathway · 2021
Not checked
515.
Li W.-X., Deng Y.-Y., Li F., Liu B., Liu H.-Y., Shi J.-S., Gong Q.-H. Icariin, a major constituent of flavonoids from Epimedium brevicornum, protects against cognitive deficits induced by chronic brain hypoperfusion via its anti-amyloidogenic effect in rats. Pharmacol. Biochem. Behav. 2015;138:40-48.
Not in our library10.1016/j.pbb.2015.09.001
516.
Yan N., Wen D.S., Zhao Y.R., Xu S.J. Epimedium sagittatum inhibits TLR4/MD-2 mediated NF-κB signaling pathway with anti-inflammatory activity. BMC Complement. Altern. Med. 2018;18:303.
Not in our library10.1186/s12906-018-2363-x
517.
Han G., Zhang C., Qian C., Na M., Ding Y., Zhao H. Total Flavonoids of Epimedium Reduce Inflammatory Reaction via AMPK/SIRT1/NFκB Signaling Pathway in Testes of Natural Aging Rats. Nat. Prod. Res. Dev. 2018;30:1489-1493.
Not in our library

Cited by papers we hold 14

Gut–Brain Axis and Neuroinflammation: The Role of Gut Permeability and the Kynurenine Pathway in Neurological Disorders · 2024
No notice
Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications · 2024
No notice
The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets · 2024
No notice
Inflammatory Processes in Alzheimer’s Disease—Pathomechanism, Diagnosis and Treatment: A Review · 2023
No notice
Role of neuroinflammation in neurodegeneration development · 2023
No notice
Microglia and Astrocytes in Alzheimer’s Disease: Significance and Summary of Recent Advances · 2023
No notice
H3K18 lactylation of senescent microglia potentiates brain aging and Alzheimer's disease through the NFκB signaling pathway · 2023
No notice
Molecular Mechanisms of Neuroinflammation in Aging and Alzheimer’s Disease Progression · 2023
No notice
Role of Microglia and Astrocytes in Alzheimer’s Disease: From Neuroinflammation to Ca2+ Homeostasis Dysregulation · 2022
No notice
Innate Immune Cell Death in Neuroinflammation and Alzheimer’s Disease · 2022
No notice
Forsythoside A Mitigates Alzheimer's-like Pathology by Inhibiting Ferroptosis-mediated Neuroinflammation via Nrf2/GPX4 Axis Activation · 2022
No notice
Solving neurodegeneration: common mechanisms and strategies for new treatments · 2022
No notice
Mitochondria as a Cellular Hub in Infection and Inflammation · 2021
No notice
Malnutrition in Older Adults—Recent Advances and Remaining Challenges · 2021
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.